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Cross-β fibrous protein polymers, reproduced and spread via nucleated polymerization 
and termed amyloids, are associated with a variety of human and animal diseases, 
including Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease 
(HD).  Various amyloids are suspected to possess transmissible (prion) properties, at least 
at a cellular level. Despite such a broad biological impact of amyloids and prions, the 
mechanism of their initial formation in vivo remains a mystery. One and the same amyloid 
protein can form various structural polymorphs (“strains”) that may differ by biological and 
pathological properties. However, molecular bases of strain differences and strain 
propagation are still poorly understood.  Simple eukaryotes like yeast also carry proteins 
that can generate and convert to distinct heritable prion strains that can be stably 
propagated and phenotypically detected. To understand the molecular mechanisms of 
initial prion nucleation, we employed a fusion of the prion domain (PrD) of yeast protein 
Sup35 to some non-Q/N-rich mammalian proteins (or peptides), associated with amyloid 
diseases. Transient overproduction of the chimeric proteins promoted nucleation of Sup35 
prions in the absence of pre-existing aggregates. Biochemical detection of the chimeric 
proteins confirmed nucleation of protein aggregates in the yeast cell. Sequence alterations 
antagonizing or enhancing amyloidogenicity of mouse PrP (associated with prion 
diseases) or human Aβ (associated with Alzheimer disease) respectively antagonize or 
enhance nucleation of a yeast prion by these proteins. Different Sup35N-PrP or Sup35N-
Aβ chimeric proteins induced different spectra of prion strains. In addition to mutational 
dissection of Aβ, the yeast-based prion nucleation assay, generated in our work, was also 
employed for identifying agents that could influence initial amyloid nucleation by Aβ. To 
specifically understand the formation and propagation of prion strains in yeast by Aβ and 
the aggregation prone repeat domain of another human protein, Tau, also associated with 
xviii 
 
AD, we employed a construct in which the Sup35 PrD or the Q/N-rich region 
encompassing first 42 amino acids of Sup35 PrD was replaced by Aβ or versions of tau 
repeat region, while the remaining portion of Sup35 remained intact. The chimeric proteins 
were able to switch from a soluble state to a non-functional prion state, that could be 
phenotypically detected. Detergent-insoluble aggregates of the chimeric proteins were 
detected biochemically, confirming the presence of the chimeric proteins in prion state. In 
vitro produced Aβ polymers converted the chimeric protein into a polymeric state upon 
transfection into yeast.  Aβ-based chimeric construct formed distinct faithfully reproduced 
strains in the yeast cell.  Our data show that prion properties of mammalian proteins 
detected in the yeast assays correspond with those found in mammals or in vitro, thus 







CHAPTER 1. INTRODUCTION AND BACKGROUND: STUDYING MAMMALIAN 
AMYLOIDOGENIC PROTEINS USING YEAST PRIONS 
 
This chapter includes data published in PLoS Genetics.  
 
Gong, H., Romanova, N. V., Allen, K. D., Chandramowlishwaran, P., Gokhale, K., 
Newnam, G. P., Mieczkowski, P. Sherman., M.Y. Chernoff, Y. O. (2012). Polyglutamine 
Toxicity Is Controlled by Prion Composition and Gene Dosage in Yeast. PLoS 
Genetics, 8(4). doi:10.1371/journal.pgen.1002634 
1.1 Summary 
Amyloid formation is implicated in more than forty animal and human diseases including 
Alzheimer’s disease (AD), Transmissible spongiform encephalopathies (TSEs), 
Parkinson’s disease (PD), Type 2 diabetes (T2D), and glaucoma. Various amyloids are 
suspected to possess transmissible (prion) properties, at least at a cellular level. Many of 
the amyloid disease-causing proteins contain intrinsically unstructured regions in a non-
amyloid form. Information about the structure of amyloid forms for some of these proteins 
have been derived from solid state NMR, cryo-EM, and molecular dynamics simulations, 
but these data mostly apply to amyloids formed in vitro. This is further complicated by the 
manifestation of amyloids as distinct structure polymorphs (strains) that may correspond 
to their different pathologies in mammalian models. Since the discovery of endogenous 
yeast prions, S. cerevisiae has become a convenient experimental model for studying the 
factors that regulate the misfolding and aggregation of mammalian amyloids. For modeling 
human amyloid diseases in yeast, the yeast homolog of the gene implicated in the disease 
is directly studied for its function. For human genes that have no yeast homologs, they are 
heterologously expressed in yeast and phenotypically characterized. These two 
approaches have been used successfully to perform a functionally or phenotypically 
analyze human disease genes in yeast. Several yeast assays for studying disease-
associated proteins such as Aβ and tau (associated with AD), PrP (associated with TSE), 
α-synuclein (associated with PD), and polyQ stretches (associated with HD) were 
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proposed previously. Yeast models for Aβ employed either a fusion of Aβ to green 
fluorescent protein (GFP) or to the functional domain of Sup35, causing a defect in 
terminating translation followed by protein oligomerization, or were directed to the 
secretory pathway, causing cytotoxicity in yeast cells. Similar models have been 
developed for studying α-synuclein (α-syn) expressing multiple copies of α-syn that t 
demonstrated a gene dosage-dependent α-syn aggregation, interfering with a broad range 
of cellular processes to exert its toxicity. These models have been useful to identify 
compounds of therapeutic potential that also showed promise in animal and/or clinical 
trials, thus confirming the translational relevance of the yeast-based assays. However, 
none of these studies have addressed if the aggregation or toxicity witnessed in all these 
diseases is exclusively driven by amyloid polymerization of the mammalian protein. They 
all address the consequence of the aggregation pathway rather than a cause of the 
disease, i.e. initial nucleation of an amyloid/prion.  Previous studies have also shown 
interactions between different mammalian proteins in yeast (e.g. Aβ and PrP, α-synuclein 
and tau) in yeast that parallel the interactions between these proteins in animals and 
human brains, and in vitro. Yeast models expressing different isoforms or mutated 
versions of human tau have also provided important insights into their aggregation 
patterns. The phosphorylation and aggregation of tau using the yeast orthologues of 
important tau kinases highlighted opportunities for the use of yeast models in studying 
mammalian amyloids. However, this has not been shown that tau aggregates formed in 
yeast are of amyloid nature. Our group has previously shown that fusions of Sup35 prion 
domain to extended polyQ tracts promoted nucleation of the Sup35 protein in the absence 
of other Q/N rich proteins. This was an important first step in addressing the cause of 
protein aggregation, i.e. initial nucleation. However, it has not been performed systemically 
for non-Q/N rich proteins primarily formed by a sporadic protein misfolding event. 
Moreover, there are no models for studying a prion formed and propagated exclusively by 
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a mammalian protein in yeast. Overall, a yeast system allowing for controlled monitoring 
and detection of switches between amyloid and non-amyloid forms, that is necessary for 
studying initial amyloid nucleation and strain formation/propagation by mammalian 
proteins is currently lacking.  
1.2 Mammalian amyloidosis and disease-related proteins 
Protein misfolding in humans and animals have been linked to more than 40 diseases, 
some of which are fatal and incurable. They include neurodegenerative disorders 
Alzheimer’s disease (AD), Parkinson’s disease (PD), transmissible spongiform 
encephalopathies (TSEs), Huntington’s diseases (HD), as well as systemic disorders such 
as type II diabetes (T2D) and glaucoma1,2,3. These diseases are typically associated with 
atleast one protein or peptide that misfold to acquire an amyloid state, in which they form 
elongated cross-β fibrous polymers, that are found in tissues or organs where the disease-
specific damage occurs1.  
 
Figure 1-1. Pathway of amyloid/prion replication by nucleated polymerization. A 
soluble native or unfolded protein with amyloidogenic sequences undergoes a 
conformational conversion via nucleation and self-assembles to form a prion polymer with 
monomer addition to the nuclei. The prion polymer is propagated into a range of different 
aggregated forms or strains exhibiting different replication and propagation properties 
(based on ref. 4). 
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 Most of these diseases are associated with the sporadic formation of amyloids, with a 
small exception of familial cases. The relationship between protein misfolding and amyloid 
formation followed by disease in the pathogenesis of protein misfolding diseases was first 
demonstrated by postmortem histopathological studies showing a hallmark 
feature of each disease is the accumulation of amyloid deposits composed of a different 
protein5. This was confirmed by genetic studies showing mutations in the genes that 
encode the proteins forming the aggregates to be transmitted by inheritance6. These 
inherited mutations which resulted in an early onset and a more severe disease than in 
sporadic cases, were also found to be associated with a higher burden of amyloid 
aggregates6. Among protein misfolding diseases, TSEs are a rare group of invariably fatal 
neurodegenerative disorders that are caused by the abnormal accumulation of infectious 
amyloids called prions. It is the transmissibility of prion disorders which distinguishes TSEs 
from other protein misfolding diseases2. Some examples of amyloid and prion diseases 
along with their associated proteins are shown (Table 1-1) and discussed below. 
Table 1-1. Amyloid/prion diseases and their associated proteins 
AMYLOID DISEASES  DISEASE-ASSOCIATED 
PROTEIN 
Alzheimer’s disease (AD) Amyloid beta (Aβ) and/tau 
Parkinson’s disease (PD) α-synuclein 
Type 2 diabetes Amylin 
Glaucoma Myocilin 




Encephalopathies (TSEs) – prion 
disease 
Prion protein (PrP) 
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1.2.1 Alzheimer’s disease (AD) and amyloid-β 
AD is typically reported as the 6th most frequent cause of death in the United States7; 
however, this is certainly an underestimate, as AD was routinely underdiagnosed in the 
past, and a significant portion of Americans over the age of 65 are dying from 
complications caused by AD. Therefore, estimates evaluating AD as the 3rd most frequent 
cause of death in the United States, and possibly in other developed countries with a long 
life-expectancy are likely to be more realistic. Moreover, the healthcare costs related to 
dementias (i.e. mostly to AD) are estimated at the level of $259 billion in the year 20168, 
and AD is one of the major factors affecting the quality of life at an advanced age9. The 
most common form of AD is late onset AD (patient age greater than 65 years), while early-
onset AD, typically familial cases, accounts for approximately 1% to 6% of all cases 
(patient age between 30 to 65 years). More than 90% of AD cases appear to be sporadic 
and usually with a late onset age10. The brains of Alzheimer’s disease (AD) patients are 
characterized by the presence of amyloid plaques and neurofibrillary tangles (NFTs) as 
diagnostic hallmarks. 
Amyloid beta (Aβ) - Amyloid plaques are caused by the aggregation of Amyloid beta 
(Aβ), a peptide that is generated through the cleavage of amyloid protein precursor (APP) 
by β-secretase and γ-secretase11(Figure 1-2). The cleavage products are extremely 
hydrophobic peptides that include Aβ1-40, Aβ1-42, and Aβ1-43, with the last two being 
more prone to aggregation and more neurotoxic while the former is found in greater 
concentrations in familial AD when compared to the latter. Although the classical view is 
that Aβ is deposited extracellularly, emerging evidence from transgenic mice  and 
human patients indicate that intracellular accumulation of Aβ in the neurons precedes 
the formation of extracellular Aβ12. Moreover, the extracellular form can re-enter the 
neuronal cells and damage them.  
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Figure 1-2.  Structural organization of human Amyloid beta (Aβ) peptide. Aβ peptide 
is a product of an abnormal proteolytic cleavage of Amyloid precursor protein (APP) by β 
and γ secretases to produce two isoforms – Aβ1-40 and/ Aβ1-42. 
Mutations in Aβ - APP mutations falling within the Amyloid beta (Aβ) sequence lead to a 
wide range of disease phenotypes, associated with familial AD (FAD). These amino acid 
substitutions have been reported to increase the amount of Aß produced, increase the 
ratio of Aß42 to Aß40, increase the aggregation potential of the mutant Aß variant, or 
promote the formation of particularly toxic conformations of aggregates, such as 
oligomers. E.g. FAD Aβ mutations, such as the Italian (E22K) and Arctic (E22G) 
mutations13, are believed to exert their pathogenic effects by inducing the formation of 
stable oligomers and protofibrils. FAD mutations, like E22G and Iowa (D23N14), that 
cluster at residues 21-23 lead to familial cerebral amyloid angiopathy (CAA), a disease 
distinct from AD characterized by microhemorrhages and often, premature death. The 
A21G mutation is another CAA-causing FAD mutations that increases total Aβ production 
in addition to causing biochemical and structural alterations in Aβ. One of the most 
interesting features of the FAD mutations within the Aβ sequence is that they lead to 
remarkable phenotypic diversity reminiscent of prion strain polymorphisms. There is 
increasing evidence that distinct amyloid structures distinguished by amyloid conformation 
dependent monoclonal antibodies have similarly distinct roles in pathology. It is possible 
that this phenotypic diversity of FAD associated with mutations within the Aβ sequence is 
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due to differences in the conformations adopted by mutant Aβ peptides13, but the effects 
of FAD mutations on aggregation kinetics and conformational and morphological changes 
of the Aβ peptide are poorly defined. 
Tau is another protein associated with AD. Tau is a major microtubule-associated protein 
present in mature neurons. Microtubules are involved in the intracellular transport of 
proteins and organelles. Additionally, they interact with proteins such as actin and 
signaling molecules. Therefore tau, through its interaction with microtubules, actin, and 
other molecules, can potentially have a significant effect on various cellular processes15. 
The phosphorylation of tau modulates its microtubule binding affinity and in doing so 
regulates the morphology of neurons and intracellular transport. However, the 
hyperphosphorylation of tau depresses this biological activity of tau. In Alzheimer disease 
(AD) and a family of related neurodegenerative diseases, called tauopathies, tau protein 
is abnormally hyperphosphorylated and aggregated into bundles of filaments that is 
polymerized into paired helical filaments (PHF), forming neurofibrillary tangle which are 
intracellular tau aggregates in AD brains15.    
Mutations in tau - The neuronal inclusions of AD are the defining neuropathological 
characteristic of frontotemporal dementias as well. The discovery of mutations in the tau 
gene in familial frontotemporal dementia and parkinsonism linked to chromosome 17 
(FTDP-17) has provided a direct link between tau dysfunction and dementing disease15. 
Known mutations produce either a reduced ability of tau to interact with microtubules, or 
an overproduction of tau isoforms with four microtubule-binding repeats. This leads in turn 
to the assembly of tau into filaments similar or identical to those found in AD brains. 
Several missense mutations also have a stimulatory effect on heparin-induced tau filament 
formation. Assembly of tau into filaments may be the gain of toxic function that is believed 
to underlie the demise of affected brain cells. Tau mutations in FTDP-17 are missense 
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mutations that are located in the microtubule-binding repeat region or close to it16. 
Mutations in exon 9 (G272V), exon 12 (V337M), and exon 13 (R406W) affect all six tau 
isoforms. By contrast, mutations in exon 10 (N279K, ΔK280, P301L, P301S and S305N) 
only affect tau isoforms with four microtubule-binding repeats or their expression16. Most 
missense mutations reduce the ability of tau to interact with microtubules, as reflected by 
a marked reduction in the ability of mutant tau to promote microtubule assembly 
The amyloid cascade hypothesis - The amyloid cascade hypothesis (Aβ hypothesis) 
suggests a causal role of amyloid peptides in AD etiology that has been the mainstream 
explanation for the pathogenesis of AD for over 25 years17. Accumulating experimental 
evidence in in vitro models, in vivo models, and from biomarkers analysis in patients 
supports the amyloid cascade and particularly Aβ-induced tau-pathology. While the 
hallmark pathology of AD is extracellular Aβ deposits and intracellular tau tangles (Figure 
1-3), several studies suggest that intracellular Aβ12 precedes extracellular Aβ, since 
intraneuronal Aβ accumulation commonly precedes its extracellular deposition in AD 
brains and transgenic mice models of AD17.  
 
Figure 1-3. A diagrammatic representation of a neuron in an AD brain.  Extracellular 
and intracellular formation of Amyloid beta plaques and intracellular formation of 
neurofibrillary tau tangles (refer [17]). 
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Also, an accumulating body of evidence has indicated that soluble forms of Aβ and tau 
work together, independently of their accumulation into plaques and tangles12, to drive 
healthy neurons into the diseased state and that the hallmark toxic properties of Aβ require 
tau. Therefore, the most likely scenario is that, Aβ is upstream of tau in AD pathogenesis 
and triggers the conversion of tau from a normal to a toxic state, but there is also evidence 
that toxic tau enhances Aβ toxicity via a feedback loop. Most importantly, the soluble toxic 
aggregates of Aβ and tau can self-propagate and spread throughout the brain by prion-
like mechanisms17. Thus, successful therapeutic intervention for AD would benefit from an 
initial detection of Aβ before the formation of plaques, tangles, and cognitive impairment 
become evident. Also, the neurofibrillary degeneration of the Alzheimer type is primarily 
seen in human neurodegenerative disorders, but it is sparsely seen in aged and in 
cognitively impaired animals, thus highlighting an urgent need for cell-based or in vitro 
models to study tau aggregation.  
1.2.2 Transmissible spongiform encephalopathies (TSEs) and PrP 
Transmissible spongiform encephalopathies (TSEs), also called as prion diseases, are a 
group of neurodegenerative disorders which have in common the formation of amyloid 
plaques. Different variants of TSE exist in many mammalian species. In humans, five 
different prion diseases have been reported to date: Kuru, Gerstmann-Straüssler-
Scheinker Syndrome (GSS), Fatal Familial Insomnia (FFI), Creutzfeldt-Jakob Disease 
(CJD), and Variably Protease-sensitive Prionopathy (VPSPr)18. Each variant presents with 
distinct clinical signs and a different prion accumulation pattern in the brain. Besides 
human prion diseases, the best-known examples due to the number of affected animals 
are: Scrapie in sheep and goat, Transmissible Mink Encephalopathy (TME), Bovine 
Spongiform Encephalopathy (BSE), and Chronic Wasting Disease (CWD) in cervids. In 
the case of TSEs, the epidemics of “mad cow” disease led to huge losses in the European 
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cattle industry20. Similar to other neurodegenerative diseases, prion diseases include 
three forms: sporadic, familial and acquired by infection.  
Prion protein, PrP - The amyloid plaques in TSEs are caused by the accumulation of an 
infectious prion protein (PrP). PrP is a cell surface protein consisting of a flexibly 
disordered N-terminal segment (residues 23-120) and a structured C-terminal domain 
(121-231) (Figure 1-4)18. The cellular form of PrP (PrPC) is converted to the disease-
associated form, known as PrP scrapie (PrPSc) in the central nervous system (CNS). The 
misfolding of PrPC to PrPSc, leads to neuronal damage and is invariably fatal. Unlike PrPC, 
PrPSc is an insoluble protein, mainly composed by β-sheet structures, partially resistant to 
proteolysis, with a high propensity to form amorphous and amyloid aggregates. In 
humans, the residues 90 to 230 of PrPSc form a structured, protease-resistant core. 
Depending on the infection portal of entry, the origin of the exogenous infectious prion 
agent, or the presence of a mutation, the form of prion diseases caused by PrP infection, 
may display distinct phenotypes called prion strains linked to the conformational diversity 
of PrPSc and they correspond to different pathological features18.  
 
Figure 1-4.  Structural organization of mouse mammalian prion protein (PrP). The 
signal peptide (1-22) is cleaved after translocation of PrP, N-terminus (23-120) is 
disordered, C-terminus of PrP (121-231) is structured, GPI (glycophosphatidyl-inositol) is 
a membrane anchor.  
Mutations in PrP – Mutations in PrP are predominantly clustered within the C-terminal 
globular domain. Two stop mutations have been observed in patients that result in a 
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truncated version of PrP- Y145stop and Q160stop20 of the human prion protein (huPrP23–
144), that lacks almost the whole structure C-terms regions and are associated with a 
hereditary amyloid disease known as PrP cerebral amyloid angiopathy. The largely 
missing C-terminal globular domain is required to import the complete PrP into the ER, 
thus retaining the truncated PrP in the cytosol, leading to an increased aggregation21. 
Mutations within the globular domain are believed either to destabilize PrPC and increase 
its propensity to misfold or to promote the formation of a toxic intermediate conformer 
during misfolding21. Alterations in the octapeptide repeat region within the unstructured N-
terminal domain are believed to alter copper and glycosaminoglycan binding affinities23. 
However, the process by which mutations outside these regions of PrP lead to 
pathogenesis is unclear, and it has been shown that one common pathogenic mutation 
outside the globular region, P102L, has no effect on the stability of PrP. The difficulties 
and costs associated with the maintenance, long incubation periods related to interspecies 
transmission barriers and an inability to adapt and study certain prion strains has 
significantly hindered progress in TSE research despite the advances achieved using 
naturally susceptible animal models. Moreover, the sequence elements or regions that 
control the aggregation patterns of wild type and mutant PrP initiating the conversion of 
PrP to a scrapie form are unknown. This indicates an opportunity for cell-based PrP 
models to be employed for further elucidation. Also, a system for the identification of PrP 
mutations associated with pathogenic isoforms may have therapeutic potential.  
1.2.3 Parkinson’s disease (PD) and α-Synuclein 
Parkinson's disease (PD) is the second most common neurodegenerative disorder, 
prevalent in 1% of the population over the age of 60 and is defined as one of the 
synucleinopathies. PD is characterized by the relatively selective loss of dopaminergic 
neuronal cells and by the presence of intraneuronal inclusions, known as Lewy bodies or 
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Lewy neurites in surviving neurons, which are considered the hallmark of PD pathology11. 
The main component of these abnormal aggregates was found to be a presynaptic protein 
called α-synuclein (α-syn), encoded by the gene SNCA, suggested to regulate 
neurotransmission11.  
α-synuclein -  α-Syn is a 140-amino acid protein of predominantly presynaptic localization 
in neurons, although it is ubiquitously expressed. It is comprised of 3 domains, (1) an N-
terminal lipid binding α-helix, (2) a non-amyloid ß component (NAC) domain and (3) an 
unstructured C-terminus. All three regions are important for the misfolding of α-syn, a 
process critical for the induction of synucleinopathies11. α-Syn is primarily a natively 
unfolded cytosolic protein and binds to membranes via its N-terminal α-helix, upon which 
it adopts an α-helical structure. It is also on the membrane that α-syn can misfold and 
begin to form aggregates. When misfolding occurs, the random coil of the NAC region 
forms β-sheets, leading to protofibril and fibril formation. The C-terminus plays a role in 
inhibiting this fibril formation, but also contains phosphorylation sites, of which 
hyperphosphorylation at S129 (pS129) is associated with α-syn pathology.  
Mutations in α-syn - Both mutations and duplication or triplication in SNCA cause 
autosomal dominant forms of PD and are the basis of the risk of developing sporadic PD, 
strongly implicating α-syn in PD pathogenesis23. The α-syn present in Lewy pathology 
exhibits a conformational change from the native soluble protein to an insoluble, fibrillar 
form, rich in β-pleated sheets. Recent studies suggested that the misfolding of α-synuclein 
causes it to aggregate and spread in certain sites, where the inflammation induced by it is 
intimately involved in the pathogenetic dysfunction underlying PD24. All of this indicates 
that α-synuclein plays a central role in the pathogenesis of PD.  
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Prion-like behavior of α-syn - Most importantly, α-syn aggregates arise first in the 
brainstem and then spread to telencephalic structures, a dynamic that is indicative of 
prion-like spread of protein aggregation. Numerous studies have shown cell-to-cell 
transmission of soluble or aggregated α-syn, both in cultured cells and in mouse brains, 
resulting in α-syn aggregation and neuronal dysfunction in the recipient cells. Importantly, 
injections of synthetic (human or mouse) α-syn fibrils also induce the recruitment of 
endogenous soluble α-syn protein to form LB-like pathology and neuronal degeneration 
in primary cell culture and in non-transgenic (wild type) host mice24. Moreover, it has also 
been shown that two different α-syn polymorphs (fibrils and ribbons) exhibit marked 
differences in their propensity to penetrate the cells, as well as in their toxicity and seeding 
aggregation in cells, suggesting the existence of different α-syn strains, thus 
demonstrating a prion-like propagation of pathological α-syn in brain, similar to prion 
diseases. Though, α-syn has been shown to propagate, the observation of subsequent 
seeding has proved to be challenging, owing to difficulties in modeling seeding 
experiments in cell culture or animal models.  
1.2.4 Type 2 diabetes (T2D) and amylin (IAPP) 
T2D is a complex metabolic disease characterized by chronic insulin resistance, 
progressive loss of β-cell function and β-cell mass, which leads to impaired insulin release 
and hyperglycemia. Genetic and environmental factors are believed to predispose some 
individuals (~20% of the population) to β-cell failure under conditions of chronic insulin 
resistance. Accumulating evidence suggests that toxic aggregates of IAPP may contribute 
to β-cell dysfunction and disease25, 26.   
Amylin – T2D, associated with Islet amyloid polypeptide (IAPP) is a 37-residue peptide 
hormone, also known as amylin, co-secreted with insulin by the endocrine β-cells of the 
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pancreas. More recently, it has been established that islet amyloid deposits are present in 
over 90% of T2D patients25. Similar to AD and PD, IAPP aggregates can also be observed 
in non-diabetic individuals, indicating that aged individuals free of T2D disease symptoms 
might be in process of developing the disease. Several studies have linked IAPP 
aggregation with β-cell loss and progression of T2D. A mutation in the IAPP gene that 
elevates its aggregation propensity is associated with early induction of T2D25. 
In addition to the recognized amyloidogenic region, human IAPP (hIAPP) 20–29, the 
peptides human or rat IAPP 30–37 and 8–20, assume β-conformation and form fibrils. 
These three amyloidogenic regions of hIAPP can be modelled as a folding intermediate 
with an intramolecular β-sheet. Although intracellular fibrils have been identified in 
experimental systems, extracellular deposition predominates in animal models and man. 
Extensive fibril accumulations replace islet cells26.  The cause and origin of IAPP 
aggregation is yet to be explored in detail.  
1.2.5 Glaucoma and myocilin 
Glaucoma is a term used to refer to a heterogeneous group of optic neuropathies that 
cause a progressive loss of vision. It is a prevalent disease (occurring in 1–2% of the world 
population over the age of 40 years) and a leading cause of blindness in the world. Many 
glaucoma cases are hereditary, and this fact has resulted in the application of genetic 
methods to investigate the pathogenic mechanisms of the disease at the molecular level3.  
Myocilin - Mutations in the glaucoma gene, MYOC, are responsible for the development 
of juvenile open-angle glaucoma and a subset of adult-onset primary open angle 
glaucoma27.  The MYOC gene encodes a 57-kDa protein known as myocilin. Myocilin is a 
secreted 55-57 kDa glycoprotein that forms dimers and multimers. Characteristic 
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structural motifs include a myosin-like domain, a leucine zipper region and an olfactomedin 
domain. Most of the mutations that have been identified in patients with POAG are 
localized in the olfactomedin domain, which is highly conserved among species. Myocilin 
is found as discrete intracellular particles surrounding the trabecular meshwork cell 
nucleus. It is secreted into tissue culture media and is also associated with the extracellular 
matrix. Although no alternative splice variants of myocilin have been reported, there are 
several posttranslational modifications of myocilin that give rise to four or more isoforms 
of the myocilin protein. Increased myocilin expression has been detected in the TM of 
patients with several different types of glaucoma28. 
Mutations in myocilin - Emerging evidence supports the hypothesis that the autosomal-
dominant early-onset form of glaucoma is caused by genetic defects in myocilin. Wild-type 
(WT) myocilin has been associated with steroid-induced glaucoma, and myocilin 
isoforms/variants have been linked to early-onset, inherited glaucoma. Elevated levels and 
aggregation of myocilin hasten increased intraocular pressure and glaucoma-
characteristic vision loss due to irreversible damage to the optic nerve.  Full-length mutant 
myocilin expressed in mammalian cells forms intracellular amyloid-containing aggregates, 
like WT and mutant myocilin (P370L)29. The WT and mutant amyloid fibrils, grown under 
a variety of conditions in a nucleation-dependent and self-propagating manner, localized 
to the C-terminal olfactomedin (OLF) domain.  Full-length mutant myocilin expressed in 
mammalian cells forms intracellular amyloid-containing aggregates as well. The molecular 
properties of the highly conserved OLF domain suggests a novel protein-based hypothesis 
for glaucoma pathogenesis. A systematic study of the molecular properties of the highly 
conserved OLF will lead to new insights in amyloid formation by myocilin, in the context of 
protein-based inheritance.  
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1.2.6 Polyglutamine (polyQ) diseases and Huntingtin 
Polyglutamine (polyQ) diseases are neurodegenerative disorders, encompassing at least 
nine heritable disorders, including Huntington disease (HD) and the spinocerebellar 
ataxias SCA1, SCA2, SCA3, SCA6, SCA7 and SCA17. Each of these disorders results 
from the expansion of a CAG repeat, coding for a glutamine tract (polyQ) that is present 
in the wild-type protein30.  
Huntingtin - In healthy individuals the polyQ tract varies between 35–50 repeats, 
depending on the disease. In patients or carriers, the polyQ tract reaches above 40 and 
often over 100 glutamines. These repeat expansion mutations are unstable, resulting in 
changes in repeat length between generations as well as between different cells and 
tissues of the same person. PolyQ expansion causes huntingtin, associated with HD, to 
acquire an unusual conformation, which facilitates their aggregation into intracellular 
inclusion bodies and causes cell toxicity. Recombinant proteins with an expanded polyQ 
stretch (51–122 glutamines) were found to form insoluble high molecular weight protein 
aggregates in vitro31. Electron micrographs of these aggregates revealed fibrillar 
structures with a morphology closely resembling that of scrapie prion rods and β-amyloid 
fibrils in AD30. These observations have shown that huntingtin could be the result of toxic 
amyloid fibrillogenesis, as has been proposed for AD.  
1.3 Yeast amyloids and prions 
Amyloids also manifest in yeast and other fungi as endogenous infectious proteins called 
“prions”, that are heritable via the cytoplasm (non-Mendelian inheritance).  To simplify the 
process of monitoring amyloid formation and propagation, the high-resolution power of 
yeast genetics tools significantly aids in amyloid characterization, and connection of yeast 
to detectable phenotypic traits simplifies amyloid monitoring32. Yeast prion proteins 
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contain so-called prion domains (PrDs) that are entirely responsible for the intermolecular 
interaction leading to the formation of an amyloid axis, and are, at least in some cases, 
distinct from domains responsible for the major cellular functions of the same proteins32. 
Yeast PrDs are generally unrelated to the major cellular function of a protein and typically 
contain a QN-rich sequence (Figure 1-5). Some yeast prions control easily detectable 
phenotypic traits, typically resulting from a partial loss of the cellular function of a protein 
because of its incorporation into prion polymers32. 
 
Figure 1-5.  An example of a typical yeast prion protein. The prion domain (PrD) 
denotes the glutamine/asparagine-rich regions (shaded in figure) that is located at the 
terminal ends of proteins, followed by a functional region that is responsible for the cellular 
function of the protein (based on ref. 32).  
Many phylogenetically unrelated prions, some of them with the potential to impact a wide 
range of cellular processes, have now been described in S. cerevisiae (Table 1-2) 
Table 1-2. Examples of yeast prion proteins and their functions 
Protein Prion Protein function 
Sup35 [PSI+] Translation termination 
Rnq1 [PIN+] Not known 
Mod5 [MOD+] tRNA modification 
enzyme 
Swi1 [SWI+] Subunit of chromatin 
remodeling complex 
 





1.3.1  Sup35 protein and [PSI+] 
The most well-characterized yeast prion forming protein is the translation termination 
factor, Sup35 (eukaryotic release factor eRF3), denoted phenotypically as [PSI+] in its 
prion form.  Sup35 consists of three domains – a Q/N-rich and oligopeptide repeat 
containing prion domain in the N terminus, a middle domain rich in charged residues, and 
a C terminus domain that is essential for Sup35 protein function (Figure 1-6)32. When 
Sup35 exists in its prion conformation, it forms insoluble aggregates, rendering it non-
functional, resulting in an increased readthrough of nonsense codon in a specifically 
designed yeast strain with a premature stop codon (Figure 1-6)32. [PSI+] can be 
phenotypically monitored using specially designed yeast strains and appropriate media32. 
It also forms amyloid fibers in vitro when seeded with amyloid aggregates mimicking the 
conformational conversion of prion proteins32 in vivo, thus providing us a model to study a 
wide range of amyloidogenic proteins and their prion behavior in a controlled manner.    
 
Figure 1-6. Structural and functional organization of the yeast prion protein, Sup35. 
N, M and C refer to Sup35N, Sup35M and Sup35C regions respectively. Numbers 
correspond to amino acid positions (not to scale). NQ and NR in Sup35N region refers to 
asparagine, glutamine rich region and oligopeptide repeat region respectively. In yeast 
strains containing ade1-14 (UGA) reporter, defect of translational termination caused by 
[PSI+] is detectable by growth on –Ade medium or color on YPD medium, due to 
accumulation of a red pigment, an intermediate in adenine biosynthesis (based on ref. 32).  
 19 
1.3.2 De novo formation of [PSI+] 
Using yeast models, it was demonstrated that de novo prion nucleation is quite rare but 
de novo prion formation by transiently overproduced prion protein can be facilitated by 
other non-homologous aggregated QN-rich protein(s)33,34,35,36. However, an efficient prion 
induction by overproduced Sup35 protein or its PrD requires the presence of another 
prion, usually [PIN+] (or [RNQ+]), a prion form of Rnq1 protein37,38. It was proposed that 
Rnq1 prion polymers nucleate the initial assembly of the Sup35 polymers (Figure 1-7). A 
transient direct association between Rnq1 polymers and Sup35 appears likely as the prion 
domains of both these proteins are rich in Q, N residues. This is true for a majority of other 
yeast prion proteins, and the presence of the other (in most cases, QN-rich) protein in an 
aggregated form was shown to reproduce the effect of Rnq1 prion on [PSI+] induction. 
 
Figure 1-7.  De novo [PSI+] nucleation by overproduction of Sup35 (or N or NM). The 
spontaneous nucleation of [PSI+] is rare but the overproduction of Sup35 or Sup35N can 
induce de novo [PSI+] formation, facilitated by the presence of another prion, e. g. [PIN+], 
the prion isoform of Rnq1 (based on ref. 32). 
De novo prion formation by transiently overproduced prion protein is also enhanced by 
actin cytoskeletal structures that are physically associated with aggregates of some 
overproduced prion-forming proteins. The simultaneous overproduction of Lsb2, a yeast 
 20 
short-lived yeast cytoskeletal protein that is triggered by stress, and Sup35, could nucleate 
[PSI+] de novo, in the absence of pre-existing [PIN+]40.  
1.3.3 [PSI+] propagation by Hsp104 
Misfolded proteins are recognized by molecular chaperones that facilitate their folding into 
native states, as specified by their primary sequence. The chaperone, Hsp104, is a 
homohexameric AAA ATPase, that is required for induced thermotolerance. In the context 
of prions, Hsp104 is required for the propagation of [PSI+]41. The levels of Hsp104 
expression is crucial for [PSI+] propagation; either an overproduction or a deletion of 
Hsp104 eliminates [PSI+], and only a transient overproduction of Hsp104 is sufficient to 
eliminate [PSI+], and when the normal levels of Hsp104 level is established, the prion state 
does not reappear41.  The proposed mechanism of [PSI+] elimination by Hsp104, called 
curing, is by breaking [PSI+] fibers into smaller prion seeds that can efficiently promote the 
prion conversion of monomeric or newly synthesized Sup35. When Hsp104 levels are 
depleted, the larger prion fibers are not fragmented into prion seeds, and thus inefficiently 
transmitted to daughter cells. On the other land, an excess of Hsp104 can disaggregate 
amyloid fibers rapidly to a degree that most of the Sup35 proteins are monomerized and 
easily refolded into their native conformations or degraded by the ubiquitin/proteasome 
pathway41.  The efficiency of polymer fragmentation by chaperones relative to polymer 
growth explains phenotypic differences between prion variants32. The polymers of strong 
[PSI+] variants are readily fragmented and therefore produce a larger number of prion units 
per cell. As the functional ends of prion polymers are active in attracting new protein 
molecules to the polymers, a larger number of polymers results in the more efficient 
immobilization of newly synthesized Sup35 protein into polymers. In contrast, polymers of 
weak [PSI+] variants are less efficiently fragmented, resulting in fewer polymer ends and 
less efficient capture of new Sup35 molecules32. Thus, weaker [PSI+] variants are 
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characterized by a larger average polymer size and a higher proportion of non-aggregated 
Sup35, causing lesser nonsense suppression in [PSI+] phenotypic assays, compared to 
stronger [PSI+] variants (Figure 1-8).  
 
Figure 1-8.  Phenotypic and biochemical differences in [PSI
+
] variants. (A) Prion 
variant strength can be measured by color on YPD or by suppression on media lacking 
adenine. (B) A smaller average size of SDS-resistant prion polymers, uncovered by semi-
denaturing detergent agarose gel electrophoresis, generally correlated with a stronger 
prion phenotype than a weaker or intermediate prion phenotype (images belong to the 
same gel and were cropped for a better demonstration).   
  
1.3.4 [PSI+] propagation by infection with prion aggregates 
The proof for protein-only hypothesis for prion propagation was first demonstrated in 
fungal proteins, Sup35, apart from another prion protein HET-s in the fungus Podospora 
anserine. Purified prion aggregates were added to yeast cells to cause infection with the 
prion32.  Since [PSI+] could also be induced de novo by the overexpression of Sup35 or its 
domains, specific prion variants were used to generate amyloid fibers at different 
temperatures, indicative of distinct conformations. After the amyloid aggregates were 
transfected into [psi−] yeast, they produced the corresponding variants of [PSI+] used for 
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transfection32. Thus, taking all of this into account, it can be conclusively said that yeast 
models employing Sup35 have been successful in delineating the molecular mechanisms 
leading to [PSI+] nucleation and propagation in yeast using different phenotypic and 
biochemical methods.  
1.4 Yeast models for amyloid nucleation and propagation  
Yeast is a powerful model eukaryotic cell for studying the fundamental cellular processes 
and protein functions that are also associated with complex multicellular eukaryotes such 
as humans. The basic mechanisms and pathways underlying neurodegenerative diseases 
such as transcriptional dysfunction, defect in trafficking, defect in clearance pathways such 
as proteasome or autophagy, mitochondrial dysfunction, transcriptional dysregulation etc., 
are highly conserved between yeast and human species and have been studied for many 
years. The universal problem of protein misfolding and its consequences also affect yeast 
and by its genome and shared attributes to human cells, yeast can be easily manipulated 
to investigate the role of prions and heritable amyloids associated with mammals and 
humans. As described above, yeast is specifically pliable for studying protein-based 
inheritance because endogenous yeast prions follow a pattern of non-mendelian 
inheritance, like mammalian prion protein, PrP, associated with TSEs32.  Thus, the basic 
molecular events involved in these processes can be studied in simple organisms such 
as yeast42. For modeling human amyloid diseases in yeast, the yeast homolog of the gene 
implicated in the disease is directly studied for its function. For human genes that have no 
yeast homologs, they are heterologously expressed in yeast and phenotypically 
characterized. These two approaches have been used successfully to perform a 
functionally or phenotypically analyze human disease genes in yeast43. Some of the yeast 
models that have helped in a better understanding of amyloid/prion formation and 
propagation in various amyloid diseases are discussed briefly as follows: 
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Table 1-3. Summary of some yeast models for studying amyloid aggregation by 
mammalian proteins 







Aβ40 or Aβ42 
fused to GFP44   
or Sup35MC45, 
MBP fused to 
Aβ4246,  deletions of 





Identified 2 drugs and 




endocytosis as a target for 
Aβ toxicity 
 
Fusions to GFP 
are toxic by itself, 




cannot be used for 
studying amyloid 
formation. They do 









Deletion of kinases 
(Δmds1 and 
Δpho85)50, co-








mechanisms of aggregation 
and toxicity between tau 
and α-syn 
It was not checked 
if the process if 
associated with a 
loss of a cellular 









Altered Sup35 with 
PrP insertions 
between N and M 
domains55 
 
PrP fused to 
Sup35MC (/C)53,54 
Identified phenotypes, 
independent of Hsp104.  
 
Confirmed that oligopeptide 
repeat region of Sup35 is 
essential for [PSI+] 
propagation 
 
It had low rates of 
switching from 
non-amyloid state 
to a heritable 
amyloid state, thus 







α- syn fused to 
GFP/ eGFP 56,60 in 
yeast mutants59, 
screening protein 
mediators of α-syn 
cytotoxicity57  
 
Demonstrated that α-syn 
interferes with a broad 
range of cellular processes 
to exert its toxicity.  
 
Identified suppressors and 
enhancers of α-syn toxicity 
  
It was not checked 
if the processes 
associated with α-
syn toxicity is 
associated with α-









Fusions of Sup35 
to polyQ of different 
lengths or 
Rnq161,62, polyQ 
expressed in the 
presence of [PIN+]63 
or attached to 
proline region64 
Promoted nucleation of the 
Sup35 protein in absence of 
other Q/N rich proteins. 
 
Proved that polyQ toxicity is 
controlled by prion 
composition and gene 
dosage in yeast 
This has not been 
done so far for 
non-Q/N-rich 
proteins in yeast 
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While proteins are the cause of these amyloid diseases and the mechanisms leading to 
the initial formation (nucleation) of these amyloids and their continuous spread 
(propagation) of the infection remains unclear. The long asymptomatic period in disease 
development has made it difficult for traditional experimental assays to identify 
pharmaceuticals that can target the initial nucleation of an amyloid or identify 
environmental factors associated with the increased/decreased incidence of these 
diseases. Therefore, prophylactic strategies to prevent nucleation or propagation of 
amyloids are essentially non-existent.  
1.5  Objectives 
The overall objective of this work is to establish yeast-based models for both 1) initial prion 
nucleation by mammalian proteins (or domains) and 2) mammalian protein-based prion 
propagation. 
Before this work was started, our lab had established a yeast-based assay for studying 
the prion properties of mammalian prion protein, PrP. Our objective was to further 
characterize the sequence elements of PrP that influenced prion nucleation by PrP in 
yeast. Most importantly, we wanted to use the prion nucleation assay to demonstrate that 
several non-Q/N rich, human amyloidogenic proteins, could nucleate a prion in yeast in 
the absence of pre-existing prions.  Specifically, we sought to examine the prion properties 
of Amyloid beta (Aβ) associated with Alzheimer’s disease (AD) by performing mutational 
analyses based on in vivo, in vitro, and computational studies for Aβ, to identify the 
sequence elements of Aβ that controlled prion nucleation by Aβ in yeast. Furthermore, we 
wanted to demonstrate an application of the assay in the identification of agents that can 
influence Aβ nucleation in yeast. In the light of many recent studies that indicate the 
propagation of misfolded mammalian proteins e.g., Aβ and another protein, microtubule 
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associated binding protein tau in AD, by a prion-like mechanism, we aimed to establish a 
yeast model for prion propagation by Aβ and tau by checking if they can propagate a prion 
state on their own or after transfection with in vitro generated amyloid seeds. This would 
confirm the translational relevance of yeast-based assays.  
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CHAPTER 2. GENERAL MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Strains 
The genotype of Saccharomyces cerevisiae strains used in this study are listed in 
Appendix Table A. Haploid [PSI+ PIN+] strains GT81-1C and GT81-1D are meiotic spore 
clones of the homozygous (except mating type) autodiploid GT81.  The [psi- pin-] strains 
GT409 and GT197 were obtained respectively from GT81-1C and GT81-1D via curing 
them of [PSI+] by guanidinium hydrochloride (GuHCl), while the [psi- PIN+] strain GT159 
was obtained via curing GT81-1C of [PSI+] using excess Hsp104. The rnq1∆ strain GT564 
was obtained by K. Gokhale in Chernoff lab via replacing the RNQ1 gene with the 
Schizosaccharomyces pombe ortholog of the HIS3 gene in the strain GT159. Strain 33G-
D373, described previously and containing a double point mutation in the ADE2 gene, was 
used for determining the functionality of the Ade2-based chimeric proteins. To make sure 
that our results are not strain-specific, we also checked [PSI+] induction by some chimeric 
constructs in the [psi- pin-] strain GT17 of the 74-D694 genotype (data not shown in thesis). 
Prototype “strong” (ψ+1-74-D694, or OT56) and “weak” (ψ+7-74-D694, or OT56) strains, 
obtained as described earlier, were employed for the phenotypic comparisons to [PSI+] 
strains, induced by chimeric constructs. GT81-1C and GT409 were employed for the 
comparisons to [PSI+] strains induced by chimeric constructs in SDD-AGE experiments. 
The [psi- pin-] strain, GT671, was used as the source for all the plasmid shuffle 
experiments in Chapter 5 and is a haploid derivative of GT81.  GT671 contained the 
sup35Δ::HIS3 transplacement on the chromosome and was maintained alive by a Sup35-
expressing plasmid, pASB2, with the LEU2 marker.  
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2.1.2 Plasmids  
Appendix Table B provides a list of all plasmids constructed or used for this work together 
with their descriptions.  
2.1.3 Primers  
Appendix Table C provides a list of all primers used for this work with their sequences and 
descriptions.  
2.1.4 Enzymes and antibodies  
Enzymes used for molecular cloning, PCR, ligation, and site-directed mutagenesis, 
including restriction endonucleases BamHI, EcoRI, XbaI, NotI, SacI, ClaI, XhoI, PstI, Mung 
Bean nuclease, Taq and Pfu DNA polymerases, and T4 DNA ligase, were purchased from 
New England Biolabs. The antibodies to Sup35N and Hsp104 were a gift of S. Lindquist 
(Whitehead Institute for Biomedical Sciences).  Sup35M (4A5) and PrP (4H11) have been 
described previously. Antibody to HA was purchased from Covance. Antibody to Aβ 
(6E10, Covance, catalog number SIG 39320) was a gift of L. Walker (Emory University 
School of Medicine). Antibody to Sup35C was a gift of Dr. D. Bedwell (University of 
Alabama, Birmingham).  
2.2 Genetic and microbiological techniques 
2.2.1 Standard yeast media and growth conditions  
Yeast cultures were grown at 30°C. Standard yeast media and standard procedures for 
yeast cultivation, phenotypic, and biochemical analysis were used68.  Cell counts were 
performed using a hemacytometer (Brightline). Optical densities of yeast cultures were 
measured at 600 nm using Shimadzu UV-2450 spectrophotometer. Standard synthetic 
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medium contains 3 μM copper sulfate (CuSO4); it was supplemented with 10, 50, 100, or 
150 μM CuSO4 as indicated to induce higher expression of PCUP1 promoter. Synthetic 
media lacking adenine, leucine, or uracil are designated as –Ade, -Leu, and -Ura, 
respectively. In all cases when the carbon source is not specifically indicated, 2% glucose 
(Glu) was used. The synthetic medium containing 2% galactose (Gal) or 2% galactose 
and 2% raffinose (Gal+Raf) instead of glucose was used to induce the GAL promoter. 
Organic complete YPD medium containing yeast extract (1%), peptone (2%) and glucose 
(2%) was used for color detection. Organic YPG medium containing glycerol (3%) instead 
of glucose was used to identify respiratory incompetent (Pet-) transformants that arose 
due to loss of mitochondrial DNA during transformation and were eliminated from further 
analysis.  Detection assay for [PSI+], based on the readthrough of the ade1-14 (UGA) 
allele, that results in growth on –Ade medium and lighter color on YPD medium is 
described previously32. Liquid cultures were grown with at least a 1/5 liquid/flask 
volumetric ratio in a shaking incubator (200-250 rpm). Yeast transformations were 
performed according to the standard Li+ protocol. Curing of [PSI+] by guanidine 
hydrochloride (GuHCl) was performed by incubating cultures for three consecutive 
passages (approximately 20-40 generations) on YPD plates with 5 mM GuHCl, followed 
by streaking out on YPD and checking individual colonies by both color and growth on -
Ade medium.  
2.2.2 Bacterial transformation procedure  
Chemicals competent DH5α E. coli were transformed using standard laboratory 




2.2.3 Yeast transformation procedure  
A single yeast colony was inoculated into 5mls YPD and cultured at 30°C with shaking to 
OD600 = 1.0-5.0. The culture was diluted with 5 ml of YPD and allowed to grow for 2-4 
hours as described. Cells were collected using centrifugation at 4000 x g for 5 minutes 
and were resuspended in 10 mls of Lithium Acetate-TE solution (LiAc-TE) (100 mM lithium 
acetate, 10 mM Tris-HCl, 1 mM EDTA, pH 8.0) and were grown for 1 hour at 30° C with 
shaking. Cells were collected and resuspended in 0.5-1 ml LiAc-TE. 100 μl of cells was 
added to a microcentrifuge tube together with 20 μg carrier DNA and 1-10 μg of plasmid 
DNA. Tubes were placed on a rotator at room temperature for 30 minutes. 700 μl PEG-
LiAc-TE (40% PEG 4000, 100 mM lithium acetate, 10 mM TrisHCl, pH 7.5, 1 mM EDTA) 
was added, and cells were rotated at room temperature for 1 hour. The sample was heat-
shocked for 5 minutes in a 42° C waterbath and was centrifuged at 3000 x g for 5 minutes 
to pellet the cells. Cells were resuspended in 150 μl water and plated on media selective 
for the plasmid.  
2.2.4 Plate assay for [PSI+] nucleation 
To check for [PSI+] nucleation in Chapters 3 and 4, plasmids bearing chimeric and control 
genes under the PCUP1 or PGAL promoter were transformed into the yeast [psi
-] strain. For 
plate assays, transformants were grown on the media. selective for the plasmid (e. g. –
Ura) containing 2% glucose as a carbon source and a background concentration (3 µM) 
of Cu++, and then velveteen replica plated onto the same medium with addition of 0, 10, 
50, 100 or 150 µM CuSO4 as specified in Figure legends (for PCUP1 constructs), or onto 
the same medium with 2% galactose instead of glucose (for PGAL constructs), to induce 
expression of the chimeric genes. After induction (usually for 2 days), plates were replica 
plated to –Ade medium with glucose and without additional CuSO4, where overexpression 
 30 
was turned over (Figure 2-1). [PSI+] formation was scored by growth on –Ade medium, 
typically after about 10 days of incubation. At least 8 (and usually more) independent 
transformants were checked per each strain/plasmid combination to assure 
reproducibility. Transformants carrying the control and experimental plasmids were 
always compared on one and the same plate. One or two representative transformants 
for each strain/plasmid combination are shown on Figures. In all cases, there were no 
differences in growth detected on the completed medium or medium selected for the 
plasmid (for the simplicity, respective images are not shown on most Figures).  
 
Figure 2-1. Scheme of plate assay for checking prion nucleation by chimeric 
proteins. 
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2.2.5 Semi-quantitative measurement of prion nucleation 
A pre-culture obtained from a fresh transformant colony was grown in the liquid synthetic 
medium selective for the plasmid up to OD600=2.5, and then inoculated into the liquid 
plasmid-selective media with additional CuSO4 (usually 100 µM) at starting concentration 
of 106 cells/ml. Cultures were incubated at 30°C with shaking, with aliquots taken at 
desired time points, washed with water, diluted appropriately  and either spotted (as serial 
decimal dilutions) or plated onto both plasmid-selective medium containing adenine (to 
count numbers of viable plasmid-containing cells) and plasmid-selective medium lacking 
adenine (e. g., –Ura-Ade), to detect [PSI+]. Frequency of [PSI+] induction was calculated 
as a ratio of the number of Ade+ colonies to the total number of viable plasmid containing 
cells plated. To ensure accuracy, only dilutions that produced plates with fewer than 500 
colonies were counted. For each construct, quantitative assay was repeated with at least 
three cultures, each originated from an independent transformant to assure reproducibility, 
and standard deviations were calculated68. Cultures with prion-inducing and control 
plasmids were always run in parallel in the same experiment. 
2.3 DNA analysis and constructions  
2.3.1 E. coli small-scale DNA isolation protocols  
Alkaline lysis method was used for quick isolation of small amounts of plasmid DNA from 
E. coli for obtaining cleaner DNA than that that obtained from the traditional boiling prep 
method.  E. coli was patched onto LB plates containing antibiotics selective for a target 
plasmid. Wooden toothpicks were used to collect cells that were then resuspended in 100 
μl of Solution I (25 mM Tris-HCl, 10 mM EDTA, 50 mM glucose, pH 8.0). 200 ul of Solution 
II (0.2 M NaOH, 1% sodium dodecyl sulfate (SDS)) was added and mixed by inversion, 
and the samples were kept on ice. 150 μl of Alkaline Lysis Solution III (5 M potassium 
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acetate, pH 5.0) was added and mixed by inversion. The sample was then incubated on 
ice for 3-5 minutes and centrifuged at 16,000 x g for 5 minutes at 4°C to pellet the cell 
debris. The supernatant was collected in a new tube, and 2 volumes of 95% ethanol was 
added, followed by vortexing to mix, and incubated at room temperature for 5 minutes. 
The sample was centrifuged at 16000 x g (4°C) for 5 min, and the supernatant was 
discarded. The pellet was washed with 70% ethanol and vortexed briefly. The sample was 
centrifuged again at 16000 x g (4°C) for 5 minutes, and the supernatant was discarded. 
The DNA pellet was dried thoroughly and resuspended in 50ul of TE (or water) containing 
10ug/ml RNase A. The sample was incubated at 37° for 30 minutes for RNA removal.   
2.3.2 DNA extraction from agarose gels 
DNA fragments generated from restriction digestion or PCR reaction were separated by 
running the fragments on a 1% TBE agarose gel stained with ethidium bromide (100V). 
Bands were visualized using a UV transilluminator (UVP Gel Doc-it 300 Imaging system.) 
DNA bands corresponding to desired products were visualized using a UV transilluminator 
(Fischer Biotech 312nm Variable Intensity Transilluminator) and excised with a scalpel 
and were purified using an IsoPure DNA Purification Prep Kit (Denville).  
2.3.3 Site-directed mutagenesis of DNA  
Mutations in the region coding for PrP or Aβ were generated using site-directed 
mutagenesis. Oligonucleotide primers that already incorporate the desired nucleotide 
substitution (point mutation) were designed using Primer X program. Unlike ordinary PCR 
primers, mutagenic primers do not anneal perfectly to the template DNA and thus, special 
considerations including GC content, primer length, and melting temperature of the 
oligonucleotide were made regarding their design. The site-directed mutagenesis 
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procedure was carried out using the protocol (Figure 2-2) in QuikChange SiteDirected 
Mutagenesis protocol (Agilent Technologies, Santa Clara, CA, USA). 
 
Figure 2-2. Scheme of site-directed mutagenesis to introduce point mutations in 
PrP (Chapter 3) or Aβ-based chimeric proteins (Chapter 4). 
2.3.4 DNA sequencing  
DNA was purified for sequencing using an IsoPure DNA Purification Prep Kit (Denville) 
and was eluted in water. DNA sequencing was performed by Eurofins MWG Operon 
Sequencing (Huntsville, AL). 
2.4 Protein Analysis  
2.4.1 Yeast total protein isolation  
For isolation of the total yeast protein,  cells grown in the liquid medium were collected by 
centrifugation at 2,000 g for 5 min at 4ºC, washed with 300 μl of ice-cold lysis buffer (25 
mM Tris pH 7.5, 0.1M NaCl, 10mM EDTA, 100 µg/ml  cycloheximide, 2 mM benzamidine, 
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20 µg/ml leupeptin, 4 µg/ml pepstatin A, 1 mM N-ethylmaleimide, 1X protease inhibitor 
cocktail form Roche Diagnostics GmbH, 2 mM PMSF),  resuspended in 2 volumes of 
icecold lysis buffer, and mixed to ~300 μl of acid washed glass beads. Cells were lysed 
by vortexing 6 times for 30 sec, with at least 1 min on ice inbetween each time. Cell debris 
were removed by centrifugation at 2,000 g for 5 min. The amount of protein in the samples 
were determined by Bradford reagent (BioRad) and normalized using lysis buffer.  
2.4.2 SDS-PAGE and western blotting 
Proteins were isolated from yeast as described and boiled for 10 minutes prior to loading 
onto SDS-polyacrylamide (SDSPAGE) gel. After electrophoresis, proteins were 
transferred onto Immobilon-P 0.45 μm polyvinylidene difluoride blotting membrane (EMD 
Millipore) or Amersham Protran Premium 0.45 μm Nitrocellulose Blotting membrane (GE 
Healthcare) and reacted to appropriate antibodies. Reaction was detected by using the 
chemiluminescent detection reagents as described in the GE Healthcare protocols. 
2.4.3 SDD-AGE  
Semi-denaturing detergent-agarose gel electrophoresis (SDD-AGE) followed by transfer 
to the nitrocellulose membrane was performed69, with the modification (addition of 0.1% 
SDS to the transfer buffer). Protein concentrations were normalized by Bradford assay.  
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CHAPTER 3. PROMOTION OF PRION NUCLEATION BY MAMMALIAN PROTEINS IN 
YEAST 
 
This chapter includes data published in Journal of Biological Chemistry.  
 
Chandramowlishwaran, P., Sun, M., Casey, K. L., Romanyuk, A. V., Grizel, A. V., 
Sopova, J. V., Rubel, A. A., Nussbaum-Krammer, C., Vorberg, I. M., and Chernoff, Y. O. 
(2018) Mammalian amyloidogenic proteins promote prion nucleation in yeast. Journal of 
Biological Chemistry. 293:3436-3450 
 
3.1 Summary 
The formation of the amyloid fibril is postulated to occur through a two-step process. First, 
the normal soluble protein is converted into small aggregates or nuclei of the prion isoform 
of that protein by a process called nucleation. Second, these nuclei seed the conversion 
of protein molecules containing the same or similar amino acid sequence thereby 
sequestering them into long fibrils. A similar molecular mechanism is employed by yeast 
prions, which are not homologous to known mammalian amyloid and prion proteins by 
sequence, and control heritable traits. We have developed a yeast-based assay that 
allows us to study the initial nucleation mechanism of any mammalian amyloidogenic 
protein. Here, we show that chimeric proteins composed of  Sup35 fragments, including 
prion-forming domain and fused to aggregation-prone regions of mammalian prion protein 
(PrP), human Amyloid beta (associated with Alzheimer’s disease), human α-synuclein 
(associated with Parkinson’s disease), human amylin (associated with Type 2 diabetes), 
or a peptide stretch within the olfactomedin domain of myocilin (associated with 
glaucoma), nucleate new Sup35 prions even in the absence of the Rnq1 prion or any other 
pre-existing nuclei. Sup35N-PrP chimera produced detergent-resistant polymers in the 
yeast cells and promoted the immobilization of endogenous Sup35 into an aggregated 
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fraction. Moreover, our data indicate that the prion/amyloid properties of PrP that are 
detected in yeast and mammalian systems are controlled by the same sequence 
elements. Different Sup35N-PrP chimeras also induced different spectra of prion strains 
in yeast.  Overall, our yeast-based nucleation assay enables us to perform genetic 
dissection of molecular processes leading to the initiation of prion and amyloid diseases. 
3.2 Specific materials and methods 
3.2.1 Materials 
Strains, plasmids, and oligonucleotide primers used in this study are described in 
Appendix tables A, B, and C respectively. The antibodies to Sup35N, Hsp104, Sup35M, 
PrP, and HA used in this study are described in Chapter 2. 
The overall scheme for construction of the chimeric genes that code for Sup35N (or NM) 
fused to mammalian amyloidogenic proteins of interest (Figure 3-1) is described in detail 
as follows. The DNA regions coding for Sup35NM (with HA tag) and PrP90-230, were 
initially inserted in the pcDNA3.1/Zeo (+) backbone; the chimeric genes coding for 
Sup35N-PrP90-230, Sup35NM-PrP90-230, and Sup35NM-PrP120-230 were initially 
generated in pcDNA3.1/Zeo (+) as well70. Then, respective constructs were excised by 
using restriction endonucleases BamHI and XbaI or SacI, and inserted under the copper-
inducible promoter (PCUP1) into a respective centromeric shuttle vector with the URA3 
marker. The plasmid pmCUP1-Sup35N-PrP120-230 was constructed via replacing the 
EcoRI fragment that contains the PCUP1-SUP35NM fragment from the plasmid pmCUP1-
Sup35NM-PrP120-230 with the EcoRI fragment that contains PCUP1-SUP35N fragment 
from the plasmid pmCUP1-Sup35N-PrP90-230. The pmCUP1-Sup35N plasmid was 
constructed by inserting the PCR-amplified BamHI-SacI fragment that contains the 
SUP35N region from the plasmid Sup35N-PrP90-230, into the pmCUP1 vector at the 
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position following the PCUP1 promoter. The genes coding for Sup35N-PrP90-119, Sup35N-
PrP90-144, Sup35N-PrP90-159, and Sup35N-PrP90-171 were constructed by inserting 
the PCR amplified BamHI-XbaI fragments, that code for the respective PrP domains, from 
the plasmid pmCUP1-Sup35N-PrP90-230 into the pmCUP1 vector at the position 
following the PCUP1 promoter. Constructs coding for the HA-tagged derivatives of the 
Sup35N and Sup35N-PrP90-230 proteins were produced by PCR-amplifying the BamHI-
SacI fragments, coding for respective proteins, from pmCUP1-Sup35N-PrP90-230 with 
primers adding an HA tag coding sequence to a C-terminal end of each fragment, and 
inserting resulting constructs into the pmCUP1 vector at the position following the PCUP1 
promoter. Both HA-tagged and non-tagged constructs produced the same results in the 
[PSI+] induction assays. The chimeric gene coding for Sup35NM-PrP90-159 was 
constructed by replacing the EcoRI fragment that contains the PCUP1-SUP35N cassette 
from the plasmid pmCUP1-Sup35N-PrP90-159, with the EcoRI fragment that contains the 
PCUP1-SUP35NM cassette from the plasmid pmCUP1-Sup35NM-PrP90-230. The chimeric 
gene coding for Sup35N-PrP23-230 was constructed by inserting the PCR amplified 
BamHI-XbaI fragment that codes for the region 23-230 of PrP from plasmid mPrPcyto49 
into the pmCUP1-Sup35NM-PrP90-230 vector at the position following the Sup35NM- 
coding sequence, replacing the PrP90-230 coding fragment. The gene coding for 
Sup35NM-Aβ1-42 was constructed by inserting the PCR amplified EcoRI-NotI fragment 
that contains Aβ1-42 from the plasmid pcDNA3.1(+)-Aβ42 (kindly provided by Dr. K. Ugen, 
University of South Florida) containing the human Aβ1-42-coding sequence72, into the 
pmCUP1-Sup35NM-PrP90-230 vector at the position following the Sup35NM-coding 
sequence, replacing the PrP90-230 coding fragment. The DNA sequence coding for Aβ1-
42 was placed under the PCUP1 promoter by inserting the PCR amplified BamHI-XbaI 
fragment that codes for Aβ1-42, from the plasmid pmCUP1-Sup35NM-Aβ1-42, into the 
pmCUP1 vector at the position following the PCUP1 promoter.  The genes coding for 
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Sup35N-Aβ1-42 and Sup35N-Aβ3-42 were constructed by replacing the EcoRI fragment 
that contains the PCUP1-SUP35NM cassette from the plasmid pmCUP1-Sup35NM-Aβ1-42, 
with the EcoRI fragment that contains PCUP1-SUP35N from the plasmid pmCUP1-Sup35N-
PrP90-230. The digestion of an additional EcoRI site at the 3rd codon of Aβ1-42 resulted 
in the generation of pmCUP1-Sup35N-Aβ3-42, while pmCUP1-Sup35N-Aβ1-42 was 
generated by incomplete digestion. To construct the series of plasmids that are more 
convenient for construction procedures using the EcoRI digestion, the pmCUP1 vector 
was digested with EcoRI, the resulting 5’ overhang was blunted using Mung Bean 
nuclease and religated with the same vector to disrupt the EcoRI site upstream the 
sequence coding for PCUP1. This plasmid, named pmCUP1-nERI, was used to construct 
pmCUP1-nERI-Sup35N-Aβ3-42 by inserting the PCR amplified BamHI-XbaI fragment that 
contains the Sup35N-Aβ3-42-coding sequence from the plasmid pmCUP1-Sup35N-Aβ3-
42, into the pmCUP1-nERI vector at the position following the PCUP1 promoter. To disrupt 
an additional EcoRI recognition site spanning the nucleotide positions 7-12 of Aβ1-42- 
coding sequence without changing the amino acid sequence, the 3rd codon of Aβ1-42 
(GAA) that codes for glutamic acid was mutated to the synonymic codon GAG, and the 
PCR amplified EcoRI-XbaI fragment containing the Aβ1-42-coding sequence with 
respective change (Aβm1-42), was inserted into the plasmid pmCUP1-nERI-Sup35N at 
the position following the sequence coding for Sup35N. In the [PSI+] induction assays, the 
Sup35N-Aβm1-42 construct produced results similar to the unmodified Sup35N-Aβ1-42 
construct. The gene coding for Sup35N-Aβ1-40 was constructed by inserting the PCR 
amplified BamHI-XbaI fragment, that contains Aβ1-40-coding sequence from the plasmid 
pmCUP1-nERI-Sup35N-Aβm1-42, into the plasmid pmCUP1-nERI-Sup35N-Aβm1-42 at 
the position following the sequence coding for Sup35N. The gene coding for Sup35NM-
Aβ1-40 was constructed by replacing the EcoRI fragment, that contains PCUP1-SUP35N 
cassette, in the plasmid pmCUP1-Sup35N-Aβ1-40 with the EcoRI fragment that contains 
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the PCUP1-SUP35NM cassette from the plasmid pmCUP1-Sup35NM-PrP90-230. 
Individual base substitutions in the pmCUP1-Sup35N-PrP90-230 was generated in the 
Aβ1-42-coding sequence using the QuikChange Site-Directed Mutagenesis protocol 
(Agilent Technologies, Santa Clara, CA, USA) and as described in Chapter 2 under 
methods.  The genes coding for Sup35N-NAC or Sup35N-IAPP or Sup35N-Myocilin were 
constructed by inserting the PCR amplified EcoRI-NotI fragment that contains NAC-HA 
and IAPP and myocilin regions from the plasmid p106.NAC, containing the human NAC-
coding sequence that corresponds to codons 61-95 of α-synuclein gene;  from the plasmid 
pJ201:66979-IAPP2_optSc containing the codons 41-70 of human Islet amyloid 
polypeptide (IAPP)- coding sequence that corresponds to residues 8-37 in mature amylin; 
and from the plasmid pMAL-p4X Myocilin WT that corresponds to codons 426-441 of 
MYOC gene respectively, into the plasmid pmCUP1-nERI-Sup35N-Aβ1-42 at the position 
following the sequence coding for Sup35N, replacing the Aβ1-42 coding fragment. Original 
plasmids p106.NAC and pJ201:66979 - IAPP2_optSc were kindly provided by Dr. V. 
Conticello from Emory University. Original plasmids pMAL-p4X Myocilin WT was kindly 
provided by Dr. R. Lieberman from Georgia Tech. The plasmids pmCUP1-Sup35NM-NAC 
and pmCUP1-Sup35NM-IAPP were constructed by inserting the PCR amplified EcoRI-
NotI fragments that contain NAC-HA and IAPP regions from pmCUP1-Sup35N-NAC and 
pmCUP1-Sup35N-IAPP, and inserted into the plasmid pcDNA3.1(Zeo)-Sup35NM-PrP90-
230 at the position following the Sup35NM-coding sequence, replacing the PrP90-230 
coding fragment. Then, respective chimeric genes were cut from plasmids 
pcDNA3.1(Zeo)-Sup35NM-NAC and pcDNA3.1(Zeo)-Sup35NM-IAPP with BamHI and 
XbaI and inserted into the pmCUP1 vector at the position following the PCUP1 promoter. 
The plasmid coding for the C-terminal fusion of Lsb2 with GFP, expressed under the PCUP1 
promoter in the pRS316 backbone was constructed earlier71. The chimeric gene coding 
for Sup35N-LacZ was constructed by inserting the PCR amplified EcoRI-XbaI fragment 
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that contains the lacZ-coding sequence from the plasmid pSVA1 (kindly provided by Dr. 
M.D. Ter-Avanesyan, Moscow) into the plasmid pmCUP1-nERI-Sup35N-Aβm1-42 at the 
position following the Sup35N- coding sequence, replacing the Aβ1-42 coding fragment. 
The gene coding for Sup35NM-LacZ was constructed by replacing the EcoRI fragment of 
the plasmid pmCUP1-Sup35N-LacZ that contains the PCUP1-SUP35N cassette with the 
EcoRI fragment that contains the PCUP1-SUP35NM cassette from the plasmid pmCUP1-
Sup35NM-PrP90-230. The gene coding for Sup35N-GFP was constructed by inserting the 
PCR amplified EcoRI-SacII fragment that contains GFP-coding sequence from the 
plasmid pmCUP1-NM-GFP71 into pmCUP1-nERI-Sup35N-Aβm1-42 at the position 
following the Sup35N-coding sequence, replacing the Aβ1-42-coding sequence. The gene 
coding for Sup35NM-Ade2 was constructed by inserting the Ade2 coding fragment from 
the plasmid pRS316GAL-Sup35NM-Ade2, into the plasmid pmCUP1-Sup35NM-Aβ1-42 
at the position following the sequence coding for Sup35NM, replacing the Aβ1-42-coding 
sequence. The gene coding for Sup35N-Ade2 was constructed by replacing the EcoRI 
fragment that contains the PCUP1-SUP35NM cassette from the plasmid pmCUP1-
Sup35NM-Ade2, with the EcoRI fragment that contains the PCUP1-SUP35NM cassette from 
the plasmid pmCUP1-Sup35N- PrP90-230. Plasmids with constructs under PGAL promoter 
were constructed by inserting the BamHI-XbaI fragments with respective chimeric genes 
from constructs with PCUP1 promoter into the centromeric HIS3 vector pLA1 [82] under the 
galactose-inducible promoter, PGAL. Plasmid pLH105, containing the HSP104 gene under 
the strong constitutive PGPD promoter, was a gift from S. Lindquist quoted earlier71. 
Plasmids pLA1-Sup35N and pLA1-Sup35, containing respectively PGAL-SUP35N and 
PGAL-SUP35N expression cassettes, were described earlier. The plasmid pmCUP1-PrP-
GFP(URA3), kindly provided by A.P. Galkin and coding for the PrP90-231-GFP chimeric 
protein, was described earlier [88]. The plasmid pmCUP1-Aβ1-42-GFP(URA3) was 
constructed via inserting the DNA fragment, encoding Aβ1–42 and obtained from the 
 41 
human brain mRNA by RT-PCR, with the addition of BamHI and SacII sites, into the 
plasmid pmCUP1-GFP [85, digested with BamHI and SacII. All regions that underwent 
PCR amplification as well as immediate flanking regions were verified by sequencing, 
performed at Eurofins MWG Operon (Huntsville, AL). Isolation of plasmid DNA from 
bacteria was performed according to standard procedures.  
 
Figure 3-1. Scheme of construction of Sup35N (or NM) fused to amyloidogenic 
protein of interest (AP). The chimeric genes contain regions coding for mammalian 
amyloidogenic proteins (AP) attached to the C-terminus of the region coding for Sup35N 
or Sup35NM. Numbers indicate amino acid position in the Sup35 sequence.  
3.2.2 Methods 
Standard protocols were used for DNA isolation, gel electrophoresis, restriction digestion, 
gel extraction, ligation, and bacterial transformation67 and are described in Chapter 2. 
Standard yeast media and standard procedures for yeast cultivation, phenotypic analysis, 
and transformation were used and are described in Chapter 2. The plate assay for [PSI+] 
nucleation and semi-quantitative/quantitative [PSI+] measurements are described in 
Chapter 2. The protein analysis including SDS-PAGE for measuring protein levels and 
SDD-AGE69 for characterizing the amyloid aggregates are described in Chapter 2. The 
scheme for mutations in the region coding for PrP were generated using site-directed 





3.3.1 Phenotypic detection of [PSI+] nucleation by PrP or Aβ in trans 
It has previously been shown that co-overproduction of some yeast prionogenic proteins 
can promote prion formation by another yeast prion protein in the strain lacking pre-
existing prions38,39. To determine if mammalian amyloidogenic proteins exhibit such an 
effect on prion formation by the yeast protein Sup35, we have overproduced the mouse 
prion protein (PrP), associated with TSEs, and the human amyloid β peptide (Aβ), 
associated with AD, in a yeast strain lacking pre-existing prions ([pin- psi-]) either 
individually or simultaneously with separately expressed Sup35 PrD, Sup35N (Figure 3-
2). In the case of PrP, we have employed the region between positions 90 and 230 which 
is sufficient to generate and maintain a prion state in mammals71. In the case of Aβ, the 
most amyloidogenic and pathogenic 42-residue72 variant (Aβ1-42) has been employed. 
We have confirmed that the PrP90-230 protein is produced in yeast (Figure. 3-3A). 
However, the levels of Aβ1-42 were below detection limits (data not shown), possibly due 
to a low proteolytic stability of this short peptide in yeast cells. Therefore, we have also 
used the PrP90-231-GFP and Aβ1-42-GFP fusion proteins that are both produced at high 
levels in yeast cells (Figure 3-3A). The PrP- and Aβ-based constructs produced amyloid-
like detergent-resistant aggregates, in yeast49, and confirmed by us (Figure 3-3B) using 
the semi-denaturing agarose gel electrophoresis, SDD-AGE69).   
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Figure 3-2. Detection of PrP- and Aβ-based constructs in yeast. (A) Expression of 
PrP90-230, PrP90-231-GFP and Aβ1-42-GFP proteins in yeast after induction with 100 
µM CuSO4, as detected by SDS-PAGE and Western blot, with anti-PrP antibody 4H11 or 
anti-Aβ antibody 6E10. Positions of molecular weight markers are indicated. (B) 
Aggregation of chimeric proteins PrP90-231-GFP and Aβ1-42-GFP in yeast, as detected 
by semi-denaturing detergent agarose gel electrophoresis (SDD-AGE), followed by 
Western blotting and reaction to anti-GFP antibody. Cell lysates were treated with 3% 
sodium lauroyl sarcosinate and run on the agarose gel. Boiling of the samples before 
electrophoresis converts aggregates to monomers. 
To detect [PSI+] formation, we employed the ade1-14 (UGA) reporter32. The [psi-] strains 
bearing this reporter are Ade- (i.e., do not grow on medium lacking adenine) and only 
rarely produce spontaneous Ade+ colonies, in part due to reversions or suppressor 
mutations. The conversion of endogenous Sup35 into a prion form leads to a termination 
defect and readthrough of ade1-14, resulting in an Ade+ phenotype. Therefore, [PSI+] 
induction can be detected as an increase in the frequency of Ade+ colonies over a low 
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background. None of the mammalian proteins (PrP90-230, PrP90-231-GFP, Aβ1-42, or 
Aβ1-42-GFP) was able to induce [PSI+] formation, both at normal levels of Sup35 and in 
the presence of excess Sup35N (Figure 3-2A, B). This contrasted with the yeast 
prionogenic QN-rich protein Lsb2 (fused to GFP), that promoted [PSI+] formation in the 




Figure 3-3. A lack of [PSI+] nucleation by PrP or Aβ in trans. (A) Overexpression of 
PrP90-230 or Aβ1-42, or B- of their respective fusions to GFP from the copper-inducible 
promoter, PCUP1 induces [PSI+] formation in the [psi
- pin-] strain neither on its own nor in 
the presence of excess Sup35N (produced under the control of the galactose inducible 
promoter, PGAL). (B) - The QN-rich prion-inducing protein Lsb2, fused to GFP is shown as 
a positive control. Cultures were pre-incubated on the medium containing additional 




3.3.2 Phenotypic detection of [PSI+] nucleation by mammalian proteins fused to Sup35N 
Next, we checked what happens if a mammalian amyloidogenic protein is physically 
attached to the fragment of Sup35 containing the PrD. We prepared a series of such 
constructs as shown in Figure 3-1. Some of them also contained an HA tag (see materials 
and methods) which does not influence the ability of the protein to induce a prion, 
according to our data (not shown). The Sup35N fragment (roughly equivalent to Sup35 
PrD), produced from a copper-inducible (PCUP1) promoter can slightly induce the formation 
of Ade+ ([PSI+]) colonies in a [pin-] strain at high concentrations of CuSO4 (e. g. see Table 
1), but this effect is weak and is not clearly detectable in plate assays (e. g. see Figure 3-
3) unless very high concentrations of CuSO4 and/or very long incubation periods are used. 
No [PSI+] induction occurs when Sup35N alone is expressed from the galactose-inducible 
PGAL promoter (e. g. see Figure 3-4C).  The Sup35NM fragment, bearing both PrD and the 
middle region (Sup35M), which contains a high concentration of charged residues and is 
responsible for keeping Sup35 in a soluble state, does not induce the formation of Ade+ 
colonies in the [pin-] strain (e. g., see Fig 3-4B, C and Table 3-1). Notably, an attachment 
of the region coding for either mouse PrP90-230 or human Aβ1-42 to the C-terminus of 
Sup35N (Figure 3-1) enabled such a chimeric construct to induce Ade+ colonies after 
incubation in the presence of CuSO4 even in conditions when induction by Sup35N alone 
was not detectable (Fig 3-4A and Table 3-1). [PSI+] induction by Sup35N-Aβ1-42 was 
stronger than that by Sup35N-PrP90-230, and could be detected even at background 
levels of CuSO4 as seen in the quantitative assay (Table 3-1). More importantly, the ability 
of these chimeric constructs to induce Ade+ colonies was not promoter-specific and did 
not depend on the presence of CuSO4 per se, as it was reproduced by using the chimeric 
constructs expressed from the PGAL promoter (Figure 3-4C). Aβ1-42 also promoted Ade+ 
formation when fused to the Sup35NM fragment and expressed from either a PGAL (Figure 
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3-4C) or PCUP1 (Figure 3-4B) promoter, albeit at a lower frequency (Table 3-1) and in the 
latter case, at higher concentrations of CuSO4 when compared to Sup35N-Aβ1-42. 
However, we have not detected Ade+ induction by the Sup35NM-PrP90-230 construct 
(Figure 3-4B, C). 
 
Figure 3-4. Phenotypic detection of prion nucleation by chimeric constructs 
containing mammalian amyloidogenic proteins, PrP or Aβ in yeast. (A), (B) and (C) 
Transient copper-induced (A and B) or galactose-induced (C) overproduction of the 
chimeric proteins containing Sup35N (A and C) or Sup35NM (B and C), fused each to 
PrP90-230 or Aβ1-42, promotes the de novo formation of [PSI+] in a [psi- pin-] strain. On 
panel C, the images from -Ade plates obtained after pre-incubation on the glucose medium 
(left column) or on the medium with 2% galactose instead of glucose (right column) are 
shown. For frequencies of [PSI+] induction, see Table 3-1.  





Frequency (+/- standard deviation) of 
Ade+ colonies per 10,000 cells after 100 
µM CuSO4 
0 hrs. 24 hrs. 
Vector 0.08+/-0.02 0.07+/-0.04 
Sup35N 0.07+/-0.05 0.31+/-0.11 
Sup35N-PrP90-230 0.07+/-0.02 8.4+/-0.7 
Sup35N-PrP120-230 0.01+/-0.02 0.25+/-0.23 
Sup35N-PrP90-144 0.11+/-0.05 54+/-17 
Sup35N-PrP90-159 0.06+/-0.05 736+/-44 
Sup35N-PrP90-171 0.07+/-0.07 35+/-6 
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We have shown that the vast majority of Ade+ colonies induced by the PrP- or Aβ-based 
chimeric constructs in the [pin-] strain retain suppression after the loss of the inducing 
plasmid and are curable by serial passages on medium containing an antiprion agent 
guanidine hydrochloride, GuHCl (Table 3-2). These data confirm that the majority of these 
colonies arise from the conversion of the endogenous Sup35 protein into [PSI+].  
 
Table 3-2. Guanidine curability of Ade+ colonies induced by chimeric constructs 
 
Inducer Colonies curable 
by GuHCl 
Total number of 
colonies tested 
Sup35N-PrP90-230 35 43 
Sup35N-PrP90-144 39 40 
Sup35N-PrP90-159 30 33 
Sup35N-PrP90-171 27 29 
Sup35N-Aβ1-42 28 29 
 
The ability to promote [PSI+] nucleation in the absence of [PIN+] upon fusion to 
Sup35N or NM is not restricted only to Aβ1-42 or PrP90-230, as three other human 
amyloidogenic peptides, namely the aggregation-prone region (“non-amyloid component”, 
or NAC) of α-synuclein, associated with PD51 and amylin (or IAPP) peptide, associated 
with type II diabetes25, and a short peptide sequence of the olfactomedin domain of 
myocilin, associated with glaucoma27,  exhibited such an effect (Figure 3-5).  
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Figure 3-5. Phenotypic detection of prion nucleation by chimeric constructs 
containing mammalian amyloidogenic peptides in yeast. Transient overproduction of 
Sup35N (or NM) fused each to NAC61-93 or IAPP41-69 or to myocilin (426-441) promotes 
the de novo formation of [PSI+] in a [psi- pin-] strain. The images from –Ade plates are 
shown, obtained without (left column) or with (right column) pre-incubation in the presence 
of additional (100 µM) CuSO4.  
 
3.3.3 Phenotypic detection of [PSI+] nucleation by multimerization prone non-
amyloidogenic proteins fused to Sup35N 
In contrast, several proteins without known amyloidogenic properties, specifically yeast 
AIR-carboxylase (Ade2), bacterial β-galactosidase (LacZ), and jellyfish green fluorescent 
protein (GFP) did not induce [PSI+] formation at any noticeable level when fused to 
Sup35N (Figure 3-6A) or NM (Figure 3-6B). Notably, some of these proteins are known to 
form multimers, and in a separate experiment employing the ade2 mutant strain, we have 
specifically shown that the Sup35N-Ade2 and Sup35NM-Ade2 constructs produce 
functional AIR carboxylase in yeast (Figure 3-6C). This confirms that these chimeric 
proteins form multimeric complexes in yeast, because the functionality of AIR carboxylase 
depends on its multimerization74. Therefore, our data show that the ability of a protein to 
 49 
promote prion nucleation in a fusion to a fragment bearing the PrD of Sup35 depends on 
the amyloidogenic properties of such a protein, rather than with its ability to form multimeric 
complexes per se.  
 
Figure 3-6. Phenotypic detection and functional analysis of prion nucleation by 
chimeric constructs containing multimerization prone, non-amyloidogenic proteins 
in yeast. (A) and (B) Transient overproduction of Sup35N fused to Ade2, LacZ, or GFP 
fails to promote de novo [PSI+] formation in a [psi- pin-] strain. The Sup35N-Aβ1-42 (A) or 
Sup35NM-Aβ1-42 (B) construct was used as a positive control. On panels A and B, the 
images from –Ade plates are shown, obtained without (left column) or with (right column) 
pre-incubation in the presence of additional (100 µM) CuSO4. (C) Functionality of the 
Ade2-based chimeric constructs. Plasmids expressing the Sup35N-Ade2 and Sup35NM-
Ade2 constructs compensate for the growth of a yeast strain, bearing the ade2 mutant 
allele, on the medium lacking adenine. 
As expected, both PrP- or Aβ- based chimeric constructs, as well as control Sup35N 




Figure 3-7. Comparison of [PSI+] induction by the PrP or Aβ-based chimeric 
constructs in the [pin-] and [PIN+] background. Chimeric constructs bearing PrP90-230 
(A) or Aβ1-42 (B), in various prion backgrounds. [PSI+] formation is detected on –Ade 
medium after transient overproduction of respective constructs from the PCUP1 promoter, 
induced by addition of 100 µM CuSO4. 
3.3.4 Analysis of proteotoxic stress induced by [PSI+] nucleated by PrP or Aβ  
Notably, a high expression of the PrP- or Aβ-based constructs (fused to either GFP or 
Sup35 PrD) did not inhibit the growth of the [pin-] yeast strain (data not shown) and did not 
increase the levels of the stress-inducible chaperone Hsp104 (Figure 3-8). These results 
show that prion induction by the PrP- or Aβ constructs is not a consequence of proteotoxic 
stress. 
 
Figure 3-8. Additional characterization of chimeric constructs in yeast. Lack of 
Hsp104 induction by chimeric constructs. Cultures were grown in the synthetic medium 
selective for the plasmids. Expression of a respective chimeric construct (as indicated) 
was induced with the addition of 100 µM CuSO4. Proteins were isolated and run on SDS-
PAGE, followed by Western blotting and reaction to the anti-Hsp104 antibody. Protein 





3.3.5 Phenotypic detection of [PIN+] appearance in [PSI+] nucleated by PrP or Aβ 
Both Sup35N-PrP90-230 and Sup35N-Aβ1-42 constructs were capable of nucleating the 
[PSI+] prion in an rnq1∆ strain, lacking the Rnq1 protein (Figure 3-9A).  This shows that a 
chimeric protein does not promote formation of [PSI+] indirectly, via inducing [PIN+], a prion 
form of Rnq1, which would in turn induce [PSI+]. However, it is known that other 
endogenous yeast QN-rich proteins in an aggregated form can substitute for the [PIN+] in 
[PSI+] induction34. To make sure that chimeric PrP- or Aβ-based constructs do not induce 
[PSI+] by generating other prions that confer a [PIN+]-like effect, we mated a sample of 
independently obtained Sup35 derivatives, induced by Sup35N-PrP90-230 or Sup35N-
Aβ1-42 in the [psi- pin-] strain, to the [psi- pin-] strain of opposite mating type, bearing a 
plasmid with HSP104 gene under a strong constitutive PGPD promoter and a plasmid with 
SUP35 gene under a galactose-inducible PGAL promoter (Figure 3-9B). Excess Hsp104 is 
known to cure [PSI+]76 but not [PIN+]34 or a majority of other known yeast prions77. 
Therefore, if [PSI+] formation was due to the formation of [PIN+] or another prion with 
similar [PSI+]-inducing capability, we would expect that the [psi-] derivative of such a [PSI+] 
isolate, cured of both the inducing plasmid and induced [PSI+], would stay [PIN+] and 
therefore be reinduced into a [PSI+] state after the overproduction of Sup35.  However, 
the vast majority of [psi-] derivatives, being cured of [PSI+] as well as of the original inducer 
plasmid and HSP104 plasmid, were unable to turn into a [PSI+] state (Ade+ phenotype) 
after Sup35 was overproduced on galactose, indicating that they stay [pin-] (Figure 3-9C). 
These data show that [PSI+] nucleation in the presence of chimeric constructs bearing 
mammalian amyloidogenic proteins is not due to the induction of [PIN+] prion or other 
yeast non-Sup35 prions with a similar effect.  
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Figure 3-9. Phenotypic detection of [PIN+] formation in [PSI+] nucleated by PrP- or 
Aβ-based chimeric constructs. (A) Induction of [PSI+] by chimeric constructs, expressed 
in the rnq1∆ strain with the addition of 100 μM CuSO4. (B) Scheme of the experiment for 
the detection of the formation [PIN+] or other prions with [PIN+]-like effect in the [PSI+] cells, 
induced by chimeric constructs. The [PSI+] colonies, induced in the [psi- pin-] strain by 
plasmids carrying Sup35N-PrP90-230 or Sup35N-Aβ1-42 (each colony originated from an 
independent transformant), were mated to the isogenic [psi- pin-] strain of the opposite 
mating type, carrying the plasmid with the HSP104 gene under a strong constitutive PGPD 
promoter and the plasmid with the SUP35 gene under galactose-inducible PGAL promoter. 
Resulting diploids (cured of [PSI+] by the constitutive overproduction of Hsp104) were then 
cured of the inducer and PGPD-HSP104 plasmids and placed onto a galactose medium to 
overexpress Sup35. Following transient induction of Sup35 on galactose, colonies were 
velveteen replica plated to the -Ade medium with glucose to check for [PSI+] reinduction. 
(C) Results of the experiment described in panel B. Only [PIN+] isolates can generate Ade+ 
(i.e., [PSI+]) colonies in these conditions. Most of the colonies derived from the [PSI+] 
isolates, that were induced by PrP- or Aβ-containing chimeric constructs, stayed [pin-]. 
 
3.3.6 Effects of alterations in PrP on [PSI+] nucleation by Sup35N-PrP   
Next, we checked if correspondence between known effects of sequence alterations on 
the amyloid formation in other systems and on prion nucleation in yeast also holds true for 
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PrP. Amino acid substitution P101L in mouse PrP (see Figure 3-10A) corresponds to the 
human mutation P102L, associated with a heritable prion disease, and is shown to cause 
disease accompanied by a production of the infectious PrP protein in mice14. In contrast, 
the substitution Q167R is shown to inhibit prion replication in mice78. In agreement with 
these data, substitutions P101L and Q167R in Sup35N-PrP90-230 construct respectively 
increased or decreased [PSI+] nucleation in the yeast assay (Figure 3-10B).  
 
Figure 3-10. Effect of mutations in PrP on [PSI+] nucleation by PrP-based chimeric 
constructs in yeast. (A) Scheme of construction of the chimeric Sup35N-PrP90-230 
derivatives. Numbers indicate amino acid positions, corresponding to mutations or 
truncations made in our work.  (B) Phenotypic detection of [PSI+] nucleation by wild type 
and mutant PrP-based chimeric constructs in yeast. Transient overproduction of the 
Sup35N-PrP constructs was induced on the medium with additional 100 μM CuSO4, and 
serial decimal dilutions were spotted onto the –Ura medium selective for the plasmid (left 
image) and onto the –Ade medium selective for [PSI+] (right image).  
 
 The region between amino acid residues 90 and 119 is required for the 
susceptibility to prion disease in mammals79-81. We have shown that a deletion of this 
region knocks out [PSI+] nucleation by the chimeric Sup35N-PrP protein in yeast (Figure 
3-11A and Table 1). Truncation of human PrP after positions 144 or 159, eliminating the 
C-terminal region, leads to a heritable disease with symptoms similar to prion disease [], 
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and truncated PrP forms amyloids in vitro80,81. We have shown that C-terminal truncations 
of mouse PrP (at positions 144, 159 or 171) in the Sup35N-PrP chimeras significantly 
increased both [PSI+] nucleation (Figure 3-11A and Table 1), and truncation at position 
159 of PrP also enabled [PSI+] nucleation in a fusion to Sup35NM (Figure 3-11A). These 
data agree with the notion that C-terminal PrP truncations trigger the formation of disease 
via nucleating prion-like aggregates, even though transmissibility of such aggregates has 
not been proven. Notably, the PrP fragment including only residues from 90 through 119 
did not promote [PSI+] nucleation when fused to Sup35 (Figure 3-11A), indicating that 
while this region is essential for prion formation (see above), it is not sufficient for this 
process.  The presence of the N-terminal region of PrP (23-89) increased [PSI+] nucleation 
in yeast, as demonstrated by the ability of the chimeric Sup35NM-PrP23-230 protein to 
nucleate [PSI+], (Figure 3-11C), in contrast to the Sup35NM-PrP90-159 construct (see 
above, Figure 3-11B). While the 23-89 region of PrP is not necessary for prion formation 
or propagation in mammals, it contains oligopeptide repeats, whose expansions are 
known to cause a heritable disease with symptoms similar to a prion disease81,82,  Overall, 
our data show that PrP alterations influence its ability to nucleate prions in yeast in the 
same direction as they influence (or are suggested to influence) prion diseases in 
mammals and humans.  
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Figure 3-11. Effect of truncations in PrP on [PSI+] nucleation by PrP-based chimeric 
constructs in yeast. (A) Comparison of [PSI+] nucleation by the Sup35N-PrP derivatives 
with various truncations after growth on the medium with additional 100 μM CuSO4. The 
Sup35N-PrP120-230 construct was not able to nucleate [PSI+], whereas the Sup35N-
PrP90-144, Sup35N-PrP90-159 and Sup35N-PrP90-171 constructs exhibited increased 
[PSI+] formation, compared to Sup35N-PrP120-230. Quantitative data are shown in Table 
3-1. (B) and (C) Sup35NM fused to PrP90-159 (B) or to PrP23-230 (C) can promote 
formation of [PSI+] in a [psi- pin-] strain after overexpression. On panels A, the images from 
–Ade plates are shown, obtained without (left column on panel A) or with (panels B and 
C, and right column on panel A) pre-incubation in the presence of additional (100 µM) 
CuSO4.  
 
3.3.7 Biochemical detection of [PSI+] aggregates by Sup35N fused to PrP  
By using semi-denaturing detergent agarose gel electrophoresis (SDD-AGE), we have 
demonstrated that the chimeric proteins containing PrP90-230 produced detergent-
resistant polymers in the yeast cells lacking pre-existing prions (Figure 3-12A) as is typical 
of yeast prions and amyloids32 and promoted the immobilization of endogenous Sup35 
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protein into an aggregated fraction (Figure 3-12B). Thus, phenotypically detectable [PSI+] 
formation coincides with physical aggregation of the inducer protein and immobilization of 
the inducee protein into aggregates. Also, the deletion of a region between amino acid 
residues 90 and 119 that previously knocked out [PSI+] nucleation by the chimeric 
Sup35N-PrP protein in yeast (Figure 3-11A and Table 3-1) essentially eliminates the 
immobilization of full-size Sup35 protein into aggregates in the yeast cells as detected by 
SDD-AGE (Figure 3-12).  C-terminal truncations of mouse PrP at positions 159 and 171 
that previously increased [PSI+] nucleation by the chimeric Sup35N-PrP proteins in yeast 
(Figure 3-11A and Table 3-1) immobilized Sup35 into amyloid aggregates (Figure 3-12C). 
 
Figure 3-12. Biochemical detection of aggregation promoted by chimeric proteins 
in yeast. (A), (B), and (C) Cell lysates of cultures expressing chimeric proteins Sup35N-
PrP90-230-HA or Sup35N-PrP90-230 derivatives in the presence of 100 μM CuSO4 
analyzed by semi-denaturing detergent agarose gel electrophoresis (SDD-AGE). On 
panel A, monomers and high molecular weight aggregates of chimeric proteins were 
detected by the anti-HA antibody for the HA-tagged Sup35N-PrP90-230. On panel B, 
immobilization of the endogenous Sup35 protein into an aggregated fraction in the 
presence of Sup35N-PrP90-230 (but not in the presence of control Sup35N) is detected 
using the anti-Sup35M antibody. On panel C, Sup35N-PrP120-230 construct cannot 
promote immobilization of endogenous Sup35 protein into an aggregated fraction, 
whereas the Sup35N-PrP90-159 and Sup35N-PrP90-171 constructs increase 
immobilization of Sup35 into an aggregated fraction, compared to Sup35N-PrP90-230. 
Equal protein amounts were loaded in each case; monomeric fractions are not shown.  
 57 
3.3.8 Protein expression levels of Sup35N-PrP derivatives  
One possible explanation for chimeric constructs, as well as for alterations of PrP or Aβ to 
influence [PSI+] nucleation could be through altering levels of chimeric proteins. To 
investigate this possibility, we have compared levels of proteins accumulated in yeast cells 
at the same concentrations of CuSO4. As described previously82, and confirmed by us 
(Figure 3-13A), Sup35N is accumulated at low levels in yeast, despite the fact that it has 
a higher prion-inducing activity in comparison to Sup35NM and Sup35. This is probably 
due to the high misfolding capability and proteolytic instability of Sup35N. The Sup35N-
PrP90-230 chimeric protein was produced at higher levels compared to Sup35N (Figure 
3-13A). However, this could not explain the increased prion-nucleating activity of Sup35N-
PrP90-230, because the Sup35N-PrP120-230 derivative, not capable of prion nucleation, 
was produced at about the same level as Sup35N-PrP90-230 (Figure 3-13B). Moreover, 
the C-terminal truncated derivatives of Sup35N-PrP, that exhibited increased [PSI+] 
nucleation, were in fact accumulated at lower levels compared to Sup35N-PrP90-230 
(Figure 3-13B).  Overall, our data show that while cellular levels of proteins used in this 
work could vary in some cases, the differences in prion nucleation cannot be explained by 







Figure 3-13. Protein expression levels of Sup35N-PrP derivatives. (A) Detection of 
the Sup35N and Sup35N-PrP90-230 proteins, tagged with HA, by using SDS-PAGE and 
Western blot with anti-HA antibody. Sup35N-PrP90-230 is accumulated at higher levels, 
compared to Sup35N. The upper band in the right lane corresponds to the dimer, 
presumably formed via disulfide bonds, as it is sensitive to β-mercaptoethanol (data not 
shown). (B) Comparison of the levels of Sup35N-PrP90-230, Sup35N-PrP120-230, 
Sup35N-PrP90-144, and Sup35N-PrP90-171 as detected by SDS-PAGE and Western 
blot with anti-Sup35N antibody. The Sup35N-PrP90-230 and Sup35N-PrP120-230 
proteins are accumulated at similar levels. This result is also confirmed by using the anti-
PrP (4H11) antibody (data not shown).  The C-terminal deletion constructs are produced 
at lower levels, compared to Sup35N-PrP90-230 and Sup35N-PrP120-230. In all cases, 
protein amounts were normalized by the Bradford assay and/or Coomassie staining. On 
all panels, “+Cu” refers to cultures growing in the presence of 100 µM CuSO4. 
 
3.3.9 Analysis of [PSI+] strains induced by Sup35N-PrP derivatives 
The Sup35 protein can produce a variety of prion variants or “strains” which presumably 
correspond to various amyloid structures34,83. These strains can be differentiated from 
each other based on both their phenotypic manifestations and biochemical patterns. 
“Stronger” strains are characterized by higher levels of nonsense codon readthrough 
(leading to better growth on –Ade medium and lighter color on complete medium in the 
case of ade1-14 reporter) and by higher mitotic stability compared to “weaker” strains. 
This is because “stronger” strains are generated by amyloid fibrils with a less rigid amyloid 
core that are more efficiently fragmented by the yeast chaperone machinery and therefore 
produce larger number of oligomeric “seeds”, making immobilization of newly synthesized 
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Sup35 and proliferation of prion state more efficient85. Once established, the prion strain 
typically faithfully reproduces its observable characteristics. 
In order to determine if mammalian amyloidogenic proteins influence the parameters of 
prion “strains” produced in yeast, we compared spectra of prion strains generated in the 
presence of different inducing constructs. For this purpose, [PSI+] isolates were divided 
into three groups designated as “strong”, “intermediate” and “weak” strains on the basis 
of growth on –Ade medium and color on complete (YPD) medium. Strain patterns were 
scored after elimination of the inducing plasmid, in order to exclude a possibility of that the 
continuous presence of a chimeric construct influences the phenotypic manifestation of a 
[PSI+] strain. Data are shown on Figure 3-14A and Appendix Figure A, and in Table 3-3. 
Sup35N-PrP90-230 induced preferentially “strong” strains, the constructs with some 
deletion PrP derivatives, such as Sup35N-PrP90-159 and Sup35N-PrP90-171 induced 




Figure 3-14. Spectra of prion strains induced by various Sup35N-PrP derivatives. 
(A) [PSI+] strains were distinguished by color on YPD and amount of growth on –Ade. 
Strong [PSI+] appeared white or white-pink on YPD and grew after 2 days on -Ade; 
intermediate [PSI+] appeared solid pink on YPD and grew after 4 days on -Ade; weak 
[PSI+] appeared red-pink on YPD and grew after 7 days on -Ade. Previously published 
prototype strains OT56 (for the strong [PSI+] prion) and OT55 (for the weak [PSI+] prion) 
are shown for the comparison to representative strong (S), weak (W) and intermediate (I) 
isolates, nucleated by the chimeric constructs (as indicated) and tested after the loss of a 
prion-inducing plasmid. YPD plates were incubated for 4 days at 30°C, followed by 3 days 
of refrigeration at 4°C for the better color development. (B) Percentages of strong, 
intermediate, and weak [PSI+] strains induced by wild type and altered Sup35N-PrP 
derivatives in a [psi- pin-] strain. More detailed information, including images for multiple 
isolates, data for the constructs containing point mutations, actual numbers and errors is 





Table 3-3. Numbers and percentages* of [PSI+] strains induced by various PrP-based 
chimeric constructs  
Inducer Strong [PSI+] Intermediate 
[PSI+] 





























































*Errors, calculated according to multinomial distribution (based on ref. 68), are shown in 
parentheses.  
3.4 Discussion 
[PIN+] independent [PSI+] nucleation. Efficient prion nucleation by the overproduced yeast 
Sup35 protein or its PrD-containing fragments typically requires the presence of another 
(usually QN-rich) protein in an aggregated form37,38,39. A fusion of some Sup35 PrD-
containing derivatives to extended polyQ tracts, resembling those associated with HD in 
humans, or to a yeast prion forming protein Rnq1 promotes nucleation of the Sup35 prion 
even in the absence of pre-existing Q/N rich yeast prions62,85.  However, expanded polyQ 
constructs and QN-rich proteins were also reported to promote Sup35 aggregation in 
trans37,, so that an addition of a polyQ or another QN-rich region to the QN-rich Sup35 
PrD could be interpreted as an expansion of Sup35 PrD. Our new data demonstrate (to 
our knowledge, for the first time) that a fusion of Sup35 PrD-containing region (Sup35N or 
Sup35NM) to a non-QN-rich mammalian protein (or protein domain) with proven 
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amyloidogenic properties is sufficient for nucleating the formation of Sup35-based prions 
in yeast cells lacking known pre-existing prions. An apparent explanation for this result is 
that mammalian proteins nucleate an amyloid in yeast, thus promoting amyloidization of 
the attached yeast prion domain (Figure 3-15). This leads to immobilization of full-length 
endogenous yeast protein into prion aggregates, thus allowing for phenotypic detection of 
a yeast prion. Importantly, a covalent attachment of mammalian “inducer” to Sup35N (or 
NM) is required for prion nucleation, as mammalian non-QN-rich amyloidogenic protein 
do not promote [PSI+] induction in trans (Figure 3-2). As expected, the Sup35N-based 
chimeric proteins are more efficient in prion nucleation than the Sup35NM-based chimeric 
proteins, apparently due to an anti-nucleation effect of the M region of Sup35, which 
contains stretches of potentially repulsive charged residues. This explains why the 
previous work by Choe group86 failed to detect [PSI+] induction by the Sup35NM-PrP-GFP 
chimeric protein in the [pin-] cells. Indeed, the Sup35NM-PrP90-230 chimeric protein also 
failed to nucleate [PSI+] in our hands (Figure 3-4C), although [PSI+] induction was detected 
for the Sup35N-PrP90-230 construct (Fig. 3-4A).  
 Role of protein amyloidogenicity in [PSI+] nucleation. Importantly, non-amyloid protein 
multimerization is not sufficient to trigger the formation of amyloid nuclei at a level 
comparable to amylodogenic oligomerization, as shown by the lack of [PSI+] induction in 
the presence of chimeric constructs, producing non-amyloidogenic multimeric proteins 
such as such as Ade2 and LacZ(Figure 3-6A,B). Fusions of Sup35N with mammalian 
amyloidogenic proteins are characterized by higher protein abundance at the same levels 
of expression, compared to proteolytically unstable Sup35N (Figure 3-13). However, the 
increased frequency of prion nucleation by Sup35N-based chimeric proteins is not simply 
due to an increase in the abundance of chimeric constructs.  This shows that the increased 
prion nucleation by chimeric constructs is a result of their amyloidogenic properties, 
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leading to the initiation of the self-assembly into an amyloid form.   
Sequence requirements for prion nucleation by PrP. The region between residues 90 and 
119 of PrP, that is known to be essential for the susceptibility to prion infection in mammals 
[], is also required for prion nucleation in yeast, while the N-terminal region of PrP (23-89) 
is dispensable for both (Figure 3-10). Mutation P101L, associated with heritable prion 
disease in mammals49,55 increased, while mutation Q167R, inhibiting prion replication in 
mammals decreased PrP-dependent prion nucleation in the yeast assay. Increased prion 
nucleating ability of the fragments lacking the C-proximal region of PrP (Figure 3-11A) 
agrees with previous reports linking C-proximal PrP truncations to a heritable neurological 
disease in humans71 and supports a notion that this disease is likely to be prion-like in 
nature. One possible explanation for this effect is that the α-rich C-proximal domain of PrP 
stabilizes the native conformation and therefore antagonizes the initiation of the cross-β 
(prion) conformation71. While the structural organization of PrP in a prion form remains a 
matter of debates (e. g., our data agree with models locating cross-β interactions within 
the region 90-170, suggesting the retention of the native secondary structure by the C-
terminal region of PrP77 and predict that the proposed β-structure at positions 160–164 is 
dispensable for prion initiation. However, our data do not necessarily contradict a 
possibility of further expansion of the amyloid core to the C-proximal region as shown for 
some PrP-based amyloids87,88. Most importantly, our yeast assay provides a tool that 
could be employed to further decipher sequential and structural requirements for initiation 
of PrP polymerization and conformational conversion.   
The impact of a nucleating construct on spectra of induced [PSI+] “strains”. Both yeast32 
and mammalian89-91 prion and amyloid proteins are known to form various variants or 
“strains” that differ from each other by phenotypic and biochemical characteristics and are 
apparently controlled by distinct protein conformations. Interestingly, we have found out 
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that the spectra of [PSI+] strains induced by different chimeric constructs differ from each 
other (Figure 3-14). One possible explanation for these data is the formation of distinct 
initial nuclei by different attached regions of chimeric proteins, followed by an expansion 
of the amyloid region to different regions of the attached Sup35N domain. Such a 
mechanism would correspond to a “deformed templating” model previously proposed for 
strain conversions in PrP prions92. In this scenario, the spectra of [PSI+] strains might 
corroborate to the differences in the “hybrid” templates formed by the fusion proteins. An 
alternative explanation is that certain strain conformations formed by Sup35N are more 
compatible, while other strain conformations are less compatible with an amyloid 
conformation formed by a specific mammalian amyloidogenic protein physically attached 
to the same molecule.  
 
Figure 3-15. Model for [PSI+] nucleation by mammalian amyloidogenic proteins. N, 
M and C – domains of Sup35, AP – mammalian amyloidogenic protein (PrP, Aβ, NAC 
region of α-synuclein, IAPP otherwise called amylin, or myocilin). Non-prion isoforms are 
designated as ellipses, prion isoforms – as squares.  
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3.5 Conclusions 
• Mammalian amyloidogenic proteins did not promote [PSI+] nucleation in trans. 
• Mammalian non-QN-rich amyloidogenic proteins or their amyloidogenic regions 
Q/N rich nucleated the Sup35 prion in yeast in the absence of pre-existing prions, 
when fused to the prion domain of Sup35 protein. 
• Non-amyloidogenic proteins (including those forming non-amyloid multimers) did 
not nucleate [PSI+] when fused to the prion domain of Sup35.  
•  [PSI+] induction by Sup35N-PrP chimera was not due to the induction of [PIN+] 
• Anti- or pro-amyloidogenic alterations in PrP respectively antagonized or promoted 
prion nucleation in yeast 
• Sup35N-PrP derivatives that nucleated [PSI+] also produced detergent-resistant 
prion polymers in the yeast cells and promoted the immobilization of endogenous 
Sup35 into an aggregated fraction.  
• Different Sup35N-PrP chimeras induced different spectra of prion strains in yeast 
  
 66 
CHAPTER 4. MUTATIONAL ANALYSIS OF AMYLOID BETA IN YEAST 
This chapter includes data published in Journal of Biological Chemistry.  
Chandramowlishwaran, P., Sun, M., Casey, K. L., Romanyuk, A. V., Grizel, A. V., 
Sopova, J. V., Rubel, A. A., Nussbaum-Krammer, C., Vorberg, I. M., and Chernoff, Y. O. 
(2018) Mammalian amyloidogenic proteins promote prion nucleation in yeast. Journal of 
Biological Chemistry. 293:3436-3450 
4.1 Summary 
In this chapter, we employed the yeast model introduced in Chapter 3 to investigate the 
effects of sequence alterations in Aβ peptide (associated with Alzheimer’s disease, (AD) 
and of certain chemicals previously linked to AD on prion nucleation by chimeric Aβ1-42-
based constructs in yeast.   Yeast assay confirms that the more aggregation-prone and 
more pathogenic Aβ derivative, Aβ1-42 is more efficient in prion nucleation than is the less 
aggregation-prone and less pathogenic Aβ derivative, Aβ1-40, confirming the previously 
reported differences in the aggregation of Aβ1-40 and Aβ1-42 in humans. A triple mutation 
(F19S, F20S, I31P) or even a single mutation I31P in Aβ1-42 knocking cross-β amyloid 
structures according the most recent structural models entirely abolishes prion nucleation 
in the yeast assay.  In contrast to Sup35N-Aβ1-42 chimera, Sup35N-Aβ1-40 chimera or 
Sup35N-Aβ1-42 with the triple mutation could not aggregate or immobilize the 
endogenous Sup35 into an aggregated fraction. The mutation D23N, associated with 
familial AD, showed increased nucleation as compared to wild type Aβ1-42, while, 
substitutions K28E or D23K respectively decreased or increased prion nucleation by 
Sup35N-Aβ1-42 in yeast. Mutations in Aβ1-42 predicted to have low or high 
amyloidogenicity by a computational model for disease-related amyloids that invoke β 
arches composed of strand-turn-strand motifs in which the two β strands interact via their 
side chains, respectively demonstrated decreased or increased nucleation by Sup35N-
Aβ1-42 in yeast. Toxicological metal ions previously suspected to promote AD, such as 
Li, Cd, and As, as well as neuronal metal ions like Zn and Cu, increased prion nucleation 
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in the presence of Sup35N-Aβ1-42, indicating the applicability of our yeast prion 
nucleation assay for testing the effects of chemical agents on the amyloid properties of 
Aβ1-42. Overall, our data confirm that the ability of Aβ1-42 to promote prion nucleation in 
yeast depends on the same parameters that control Aβ1-42 oligomerization and 
aggregation in humans and in vitro, and that the yeast assay can be used for dissecting 
the sequence elements and environmental factors influencing amyloid nucleation by Aβ1-
42. 
4.2 Specific materials and methods 
4.2.1 Materials 
The strains, plasmids, and primers used in this study are listed in Appendix Tables A, B, 
and C respectively. Sup35C antibody used in this study is described in Chapter 2.    
4.2.2 Methods 
Standard protocols were used for DNA isolation, gel electrophoresis, restriction digestion, 
gel extraction, ligation, and bacterial transformation and are described in Chapter 2. 
Standard yeast media and standard procedures for yeast cultivation, phenotypic analysis, 
and transformation were used and are described in Chapter 2. The plate assay for [PSI+] 
nucleation and semi-quantitative/quantitative [PSI+] measurements are described in 
Chapter 2. The protocol for protein analysis including SDS-PAGE for measuring protein 
levels and SDD-AGE for characterizing the amyloid aggregates are described in Chapter 
2. The scheme for mutations in the region coding for Aβ1-42 were generated using site-
directed mutagenesis and are described in Chapter 2. 
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4.2.2.1 Scheme of screening assay for agents influencing [PSI+] nucleation 
In the initial plate assay, a chemical to be tested was absorbed on the sterile paper filter 
and placed in the middle of the freshly-made lawn of the yeast [psi- pin-] reporter strain, 
bearing Sup35N-Aβ construct and prepared on a petri dish with the medium inducing 
expression of the chimeric Sup35N-Aβ1-42 construct (e. g. galactose for the PGAL 
promoter). Toxicological compounds, such as Cd and As salts or even biologically relevant 
ions at high concentrations, generate a halo of growth inhibition around the filter in these 
conditions. This confirms that compound is taken up by the yeast cells. After the lawn is 
grown, it was replica plated onto –Ade medium, where prion formation can be detected by 
growth due to nonsense-suppression of the ade1-14 reporter (see Figure 4-1). We used 
H2O as the experimental control and experimental metal ion containing solvents such as 
300µM CuSO4, 300µM LiCl, 300µM ZnCl2, 150µM AsCl2, and 100µM CdCl2. The 
concentrations for the nucleation experiment was adjusted based on the toxicity of the 
compound being tested.  As and Cd generated toxicity and thus their concentrations were 
lowered until they didn’t form a halo of inhibition after they were added to the filter paper 
disc in the presence of yeast cells.  
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Figure 4-1. Scheme of plate assay to check for agents that influence [PSI+] 
nucleation by Sup35N-Aβ chimeric protein  
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4.2.2.2 ArchCandy algorithm for prediction of Aβ mutations  
The mutations in Aβ with a high or low amyloidogenic score to predict amyloid forming 
potential or lack thereof, was based on the ArchCandy-1.0 program that detects regions 
in protein sequences that have a potential to form amyloids93. The scores for the Aβ 
mutants were generated and provided by Dr. Andrey Kajava at Montpellier University, 
France as a collaborative project.  The core structural element of a majority of naturally-
occurring and disease-related amyloid fibrils is a β-arcade representing a parallel and in 
register stacks of β-strand-loop-β-strand motifs called β-arches93. "ArchCandy" was 
developed based on an assumption that protein sequences that are able to form β-arcades 
are amyloidogenic. The amyloidogenicity scores of the mutations H13L, A21E D23A, 
G25V, K28E and F19K are listed here. The mutants were predicted to have lower 
amyloidogenicity based on a score of 0.549 using the algorithm explained previously. The 
mutants tested were Aβ(1-42) K28E with the amino acid sequence 
DAEFRHDSGYEVHHQKLVFFAEDVGSNEGAIIGLMVGGVVIA), Aβ(1-42) G25V 
with the amino acid sequence 
DAEFRHDSGYEVHHQKLVFFAEDVVSNKGAIIGLMVGGVVIA), and Aβ(1-42) 
F19K with the amino acid sequence 
(DAEFRHDSGYEVHHQKLVKFAEDVGSNKGAIIGLMVGGVVIA). The mutants 
were predicted to have higher amyloidogenicity based on a score of 0.763. The mutants 
tested were Aβ(1-42) A21E, D23A with the amino acid sequence 
(DAEFRHDSGYEVHHQKLVFFEEAVGSNKGAIIGLMVGGVVIA) and Aβ(1-42) 




A unique feature of our experimental system is that in vivo (inside a living organism) 
protein misfolding and disease formation of human proteins, triggering the amyloid 
nucleation (earliest formation or the very first step) process, can be induced at our will by 
increasing the level of production of a chimeric protein. This somewhat mimics a proposed 
scenario of Alzheimer’s disease (AD) development in humans, where increased 
production of Alzheimer’s protein is implicated in the initial amyloid formation.  
In chapter 3, we overproduced the human amyloid β peptide (Aβ), associated with AD, in 
a yeast strain lacking pre-existing prions ([pin- psi-]) either individually or simultaneously 
with separately expressed Sup35N (Figure 3-2).  Aβ1-42 or Aβ1-42-GFP could not induce 
[PSI+] formation, both at normal levels of Sup35 and in the presence of excess Sup35N 
(Figure 3-3A, B). However, Aβ1-42 promoted [PSI+] nucleation when attached to the 
Sup35 prion domain (Figure 3-4A). The Ade+ colonies induced by the Aβ-based chimeric 
constructs in the [pin-] strain retained suppression after the loss of the inducing plasmid 
and were curable by serial passages on medium containing an antiprion agent guanidine 
hydrochloride, GuHCl. These data confirmed that the majority of these colonies arise from 
the conversion of the endogenous Sup35 protein into a prion form, [PSI+].  
Next, we checked if alterations (deletions or mutations) in Aβ1-42 known to influence prion 
propagation and disease in mammals have similar effects in yeast. Using in vitro models 
as well as the most recent structural model of Aβ1-42 polymers models94,95 demonstrating 
the secondary structure of Aβ(1–42) molecule which consists of two molecules per Aβ(1–
42) polymer unit and comprises five in-register parallel intermolecular β-strands [i.e., 2–6 
(β1), 15–18 (β2), 26–28 (β3), 30–32 (β4), and 39–42 (β5)]., we mapped the locations of 
deletions and mutations in Aβ(1–42), that are known or predicted to influence the 
 72 
aggregation patterns of Aβ(1–42). The alterations made in Aβ (1–42) are indicated as grey 
dotted lines (for deletions) and orange dotted lines (for point mutations). The mutations in 
red indicate those were predicted by ArchCandy algorithm (refer Methods) to have lower 
or higher amyloidogenicity based on a β arcade model of disease related amyloids; the 
mutations in green indicate those that were based on in vitro models or recent structural 
models; the mutation in purple indicates a familial AD Iowa mutation. 
 
Figure 4-2. The location of alterations in Aβ(1–42) based on the secondary structure 
of Aβ(1–42) molecule. The model is based on the latest structure of a polymorph of Aβ 
(1–42) amyloid fibril mostly based on solid-state NMR (as per ref. 95, 96). The alterations 
made in Aβ(1–42) are indicated as dotted lines in different colors (refer text above).  
 
4.3.1 Effects of truncations in Aβ1-42 on [PSI+] nucleation by Sup35N-Aβ1-42 
Several variants of Aβ peptide exist in humans, of which Aβ1-42 and Aβ1-40 (lacking the 
last two amino acid residues) are the most abundant ones96. Of these two, Aβ1-42 is 
considered to be the most amyloidogenic and most pathogenic form in humans97. In yeast, 
Sup35N-Aβ1-40 nucleated [PSI+] much less efficiently than did Sup35N-Aβ1-42 (Figure 
4-3A), while Sup35NM-Aβ1-40 did not nucleate [PSI+] at all (Figure 4-3B). Notably, 
removal of the two N-terminal amino acid residues of Aβ within the chimeric construct did 
not inhibit [PSI+] nucleation (Figure 4-3C), in an agreement with structural models placing 
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the N-terminal region of Aβ outside of amyloid core94,95.  
 
Figure 4-3. [PSI+] nucleation by chimeric constructs with various Aβ truncations in 
yeast. (A) The Sup35N-Aβ1-40 construct shows decreased [PSI+] induction in a [psi- pin-
] strain, compared to Sup35N-Aβ1-42. (B) The Sup35NM-Aβ1-40 construct does not 
induce [PSI+] formation in a [psi- pin-] strain.  [PSI+] induction by Sup35NM-Aβ1-42 is 
shown as a positive control. (C) The Sup35N-Aβ3-42 construct induces [PSI+] formation 
in a [psi- pin-] strain at levels comparable to Sup35N-Aβ1-42. On panels A through C, the 
images from –Ade plates are shown, without (left column) or with (right column) pre-
incubation on the medium with additional 100 µM CuSO4. For quantitative data, see Table 
4-1.  




Frequency (+/- standard deviation) of Ade+ 
colonies per 10,000 cells after 100 µM CuSO4 
0 hrs. 24 hrs. 
Sup35N-Aβ1-42 1.19+/-0.16 1178+/-208 
Sup35N-Aβ1-40 0.09+/-0.08 2.0+/-0.9 
Sup35N-Aβ1-42*** (F19S, 
F20S, I31P) 0.09+/-0.05 0.36+/-0.28 
Sup35NM 0.07+/-0.06 0.13+/-0.04 
Sup35NM-Aβ1-42 0.11+/-0.03 30+/-7 
Sup35NM-Aβ1-42*** (F19S, 
F20S, I31P) 0.01+/-0.02 0.04+/-0.03 
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4.3.2 Effects of mutations in Aβ1-42 on [PSI+] nucleation by Sup35N-Aβ1-42 
We have also generated several mutations at the positions of Aβ1-42 known to influence 
amyloid formation98,99,100.  
4.3.2.1 Based on an in vitro or a familial AD model  
Previous in vitro experiments and structural data identified positions 19, 20 and 31 as 
being important for amyloid formation by Aβ94,95 and located within intramolecular cross-β 
sheets of Aβ1-40 polymers95. However, according to the most recent structural model of 
Aβ1-42 polymers95 only position 31 is located within one of the β-strands, while positions 
19 and 20 are involved in hydrophobic interactions. Indeed, the substitution I31P, breaking 
the proposed β4-strand95, greatly decreased [PSI+] nucleation by Sup35N-Aβ1-42, while 
the substitution F19S caused only a mild decrease, and the substitution F20S had almost 
no effect (Figure 4-4A). Notably, the triple mutation F19S, F20S, I31P entirely abolished 
[PSI+] nucleation by both Sup35N-Aβ1-42 (Figure 4-4A, Table 4-1) and Sup35NM-Aβ1-42 
(Table 4-1). On the contrary, chimeric constructs with a substitution D23N, a so-called 
“Iowa mutation” associated with the heritable form of AD14, significantly increased [PSI+] 
nucleation in yeast (Figure 4-4B). These data confirm that effects Aβ alterations in the 
yeast model parallel those detected in vitro or in humans.  
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Figure 4-4. [PSI+] nucleation by Aβ1-42 with mutations from in vitro data and a 
familial AD model, fused to Sup35N (A) Effects of base substitutions at positions 19, 20 
and 31 of Aβ, and of a combination of these substitutions on [PSI+] induction by the 
chimeric Sup35N-Aβ1-42 constructs in a [psi- pin-] strain, compared to wild type Sup35N-
Aβ1-42. (B) The D23N substitution increases the ability of Sup35N-Aβ1-42 to induce [PSI+] 
formation in a [psi- pin-] strain.  Images from –Ade plates are shown, obtained after pre-
incubation on the medium with additional 0, 10, or 50μM CuSO4, from left to right. For 
quantitative data for some of the chimeras, see Table 4-1. 
4.3.2.2 Based on structural and computational AD models  
Based on the recent structural models for Aβ1-4294,95 fibril including the high-resolution 
structures of Aβ1-42 amyloids based on solid-state NMR (Figure 5-2), a substitution K28E 
would affect the β3 strand of Aβ1-42 fibril (Figure 4-2). This was contrary to previous solid-
state NMR studies of Aβ1-40 that identified the existence of a salt bridge between the side 
chains of residues Asp23 and Lys28 in the Aβ1-40 fibril101,102, considered to be one of the 
hallmarks of Aβ aggregation and found to be present in Aβ1-42 amyloid fibrils.  To 
reproduce the structural data demonstrated by the latest solid-state NMR studies for Aβ1-
42 in yeast, we made substitutions K28E as well as a substitution D23K that would change 
the charge on Asp23 to that of Lys28. Furthermore, we also made a reciprocal mutation 
of D23K, K28E that would change the charges on Asp23 and Lys28 but would restore the 
interactions between them and stabilize the Aβ fibril if they formed a salt-bridge in the first 
place. The substitution K28E significantly decreased [PSI+] nucleation by Sup35N-Aβ1-
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42. On the contrary, the substitution D23K showed slightly increased [PSI+] nucleation 
compared to Sup35N-Aβ1-42. However, the reciprocal substitution D23K, K28E showed 
an increased [PSI+] nucleation compared to Sup35N-Aβ1-42 with substitution K28E but 
less than Sup35N-Aβ1-42 or Sup35N-Aβ1-42 with D23K substitution.  
Also, based on a recent computational model of disease-related amyloids93 that suggest 
that complexes of 2 or more β arches, a structural motif in amyloid proteins may form 
nucleation complexes for amyloid fibrillogenesis in vivo, we made mutations in Aβ1-42 
that were predicted to have a high or low amyloidogenicity score depending on their 
formation of β arches, and fused them to Sup35N. As per the ArchCandy algorithm for 
predicting the formation of β arches, substitutions H13L and A21E, D23A were predicted 
to have a high amyloidogenicity score and substitutions G25V, F19K, and K28E were 
predicted to have a low amyloidogenicity score in comparison to Aβ1-42 without any 
mutations. In comparison to Sup35N-Aβ1-42 without any alterations, the substitutions 
A21E, D23A slightly increased [PSI+] nucleation by Sup35N-Aβ1-42. On the contrary, the 
substitutions F19K and K28E greatly decreased [PSI+] nucleation by Sup35N-Aβ1-42 
while the substitutions H13L and G25V showed comparable levels of [PSI+] nucleation to 
Sup35N-Aβ1-42, although they do demonstrate slight differences in [PSI+] nucleation 
compared to Sup35N-Aβ1-42 in terms of growth on -Ade but they had to be detected 
within 5 days of incubation (short period of incubation) on -Ade media and was hard to 
accurately demonstrate in this format of plate assay.  
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Figure 4-5. [PSI+] nucleation by Aβ1-42 with mutations from structural models, 
fused to Sup35N. (A) A D23K substitution slightly increases the ability of Sup35N-Aβ1-
42 to induce [PSI+] formation in a [psi- pin-] strain while K28E substitution has an opposite 
effect on [PSI+] induction. However, a reciprocal substitution of D23K, K28E restores the 
ability of Sup35N-Aβ1-42 to induce [PSI+]. Sup35N-Aβ1-42 is used as a control. (B) Effects 
of substitutions at different positions of Aβ, on [PSI+] induction by the chimeric Sup35N-
Aβ1-42 constructs in a [psi- pin-] strain, compared to wild type Sup35N-Aβ1-42. On panels 
A and B, the images from –Ade plates are shown, without (left column) or with (right 
column) pre-incubation on the medium with additional 100 µM CuSO4.  
 
4.3.3 Biochemical detection of [PSI+] aggregates by Sup35N fused to Aβ1-42 derivatives 
By using semi-denaturing detergent agarose gel electrophoresis69 (SDD-AGE), we have 
demonstrated that the chimeric proteins containing Aβ1-42 produced detergent-resistant 
polymers in the yeast cells lacking pre-existing prions (Figure 4-6A) as is typical of yeast 
prions and amyloids32 and promoted the immobilization of endogenous Sup35 protein into 
an aggregated fraction (Figure 4-6B). Thus, phenotypically detectable [PSI+] formation 
coincides with physical aggregation of the inducer protein and immobilization of the 
inducee protein into aggregates. The Sup35N-Aβ1-40 construct (Figure 4-6A) and 
Sup35N-Aβ1-42 triple mutant (F19S, F20S, I31P; Figure 4-4B) neither formed detergent-
resistant polymers at detectable levels nor immobilized Sup35 into an aggregated state, 
according to SDD-AGE. Overall, our data show that effects of Aβ alterations of [PSI+] 
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Figure 4-6. Biochemical detection of the effects of Aβ alterations on protein 
aggregation in yeast. Cultures were grown in the presence of 100 µM CuSO4. (A) In 
contrast to Sup35N-Aβ1-42, the Sup35N-Aβ1-40 construct does not efficiently aggregate 
(left image) and does not immobilize endogenous Sup35 into an aggregated fraction (right 
image). The small Aβ monomers are not seen on the left image as they have run out of 
the gel.  (B) The Sup35N-Aβ1-42 protein with triple F19S, F20S, I31P substitution does 
not aggregate (left image) and does not immobilize endogenous Sup35 when probed with 
into an aggregated fraction (right image). The image for N-Aβ1-42 (on the left) and the 
images for N and N-Aβ1-42 (on the right) in panel B are the same images that were shown 
on Fig 3, A and B, respectively. These images are repeated here as positive (N-Aβ1-42) 
and negative (N) controls. 
4.3.4 Protein expression levels of Sup35N-Aβ1-42 derivatives    
One possible explanation for chimeric constructs, as well as for alterations of Aβ to 
influence [PSI+] nucleation could be through altering levels of chimeric proteins. To 
investigate this possibility, we have compared levels of Sup35N-Aβ1-42-based chimeric 
proteins accumulated in yeast cells at the same concentrations of CuSO4. The prion-
inducing Sup35N-Aβ1-42 construct was accumulated at the same levels as prion non-
inducing Sup35N-Aβ1-40 and Sup35N-Aβ1-42 triple F19S, F20S, I31P mutant (Figure 4-
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7A, B) respectively. The [PSI+]-inducing Sup35NM-Aβ1-42 construct was accumulated at 
the same level as non-inducing Sup35NM-Aβ1-40 construct, and both were less abundant 
than the non-inducing control, Sup35NM (Figure 4-7C). Overall, our data show that while 
cellular levels of proteins used in this work could vary in some cases, the differences in 
prion nucleation cannot be explained by differences in protein abundance. 
 
Figure 4-7. Detection of chimeric proteins in yeast. (A) Comparison of the levels of 
Sup35N-Aβ1-40 and Sup35N-Aβ1-42 constructs as detected by SDS-PAGE and Western 
blot with anti-Aβ (6E10) antibody. Both proteins are accumulated at similar levels. (B) 
Comparison of the levels of Sup35N-Aβ1-42 and Sup35N-Aβ1-42*** (triple F19S, F20S, 
I31P substitution) constructs as detected by SDS-PAGE and Western blot with anti-Aβ 
(6E10) antibody. Both proteins are accumulated at similar levels. (C) Comparison of the 
levels of Sup35NM, Sup35NM-Aβ1-40, and Sup35NM-Aβ1-42 constructs as detected by 
SDS-PAGE and Western blotting with anti-Sup35M antibody. Chimeric protein are 
accumulated at similar levels, which are lower than the level of accumulation of Sup35NM. 
In all cases, protein amounts were normalized by the Bradford assay and/or Coomassie 
staining. On panel E, the upper band corresponding to full-length Sup35 protein also 
serves as a loading control. On all panels, “+Cu” refers to cultures growing in the presence 
of 100 µM CuSO4. 
4.3.5 Analysis of [PSI+] strains induced by Sup35N-Aβ1-42 derivatives  
 As explained in Chapter 4, the Sup35 protein can produce a variety of prion 
variants or “strains” which presumably correspond to various amyloid structures that can 
be differentiated from each other based on both their phenotypic manifestations and 
biochemical patterns32. Once established, the prion strain typically faithfully reproduces its 
observable characteristics. To determine if mammalian amyloidogenic proteins influence 
the parameters of prion “strains” produced in yeast, we compared spectra of prion strains 
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generated in the presence of different inducing constructs. For this purpose, [PSI+] isolates 
were analyzed as described for Sup35N-PrP derivatives in Chapter 3.  Data are shown on 
Figure 4-8, Appendix Figure A, Table 4-2. While Sup35N-Aβ1-42 exclusively “strong” 
strains and Sup35N-Aβ1-40 produced [PSI+] isolates of all three classes. Some point 
mutations changed a spectrum of the induced [PSI+] strains. The Sup35N-Aβ1-42 
construct with mutation D23N induced preferentially intermediate [PSI+] isolates, while 
construct with the mutation K28E construct induced preferentially weak and intermediate 
[PSI+] isolates. These results indicate that the preferable type of a yeast prion strain, in 
part, depends on the mammalian amyloidogenic protein used in the inducing construct.  
 
Figure 4-8. Spectra of prion strains induced by various Sup35N-Aβ derivatives. (A) 
[PSI+] strains were analyzed as shown in Figure 3-14. (B) Percentages of strong, 
intermediate, and weak [PSI+] strains induced by wild type and altered Sup35N-Aβ 
derivatives in a [psi- pin-] strain. More detailed information, including images for multiple 
isolates, data for the constructs containing point mutations, actual numbers and errors is 
presented in Appendix figure A and Table 4-2  
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Table 4-2. Numbers and percentages* of [PSI+] strains induced by various Aβ-based 
chimeric constructs 
Inducer Strong [PSI+] Intermediate 
[PSI+] 










































4.3.6 [PSI+] nucleation by Sup35N-Aβ1-42 in the presence of metal ions      
 First, we used a modified yeast-based plate assay (Figure 4-1). for testing 
compounds that were previously linked or suspected to be linked to AD. These included 
metal ions suspected in AD (e. g. Cd, As, Pb, Al, Cu, Fe, Li and Zn) 104,105, out of which Al, 
Cu, Fe, and Zn are neuronal metal ions and the rest are toxicological metal ions. Our pilot 
experiments have indeed demonstrated that in plate assays, some metal ions (specifically, 
Zn, Li, Cd, and As, and to a lesser extent, Fe) increased formation of Ade+ colonies in the 






Figure 4-9. Identification of metal ions influencing [PSI+] nucleation by Aβ1-42 fused 
to Sup35N in yeast. Yeast cells bearing Sup35N-Aβ1-42 under the PGAL promoter in a 
[psi- pin-] strain, were incubated on the galactose medium in the presence of H2O (control) 
or presence of 300µM CuSO4, 300µM LiCl, 300µM ZnCl2, 150µM AsCl2, and 100µM CdCl2. 
and velveteen replicated plated into –Ade media for [PSI+] detection.  
 
4.4 Discussion 
Amino acid residues influencing prion nucleation by Aβ. In the case of Aβ peptide, data 
from the yeast assay are also in a good agreement with existing results obtained in other 
systems. For example, the Aβ40 peptide lacking the two C-terminal hydrophobic amino 
acids, I41 and A42, is considered to be less aggregation-prone and is a typically non-
pathogenic Aβ isoform in humans98. This peptide is drastically inefficient in prion 
nucleation in the yeast assay, compared to the highly amyloidogenic and presumably 
pathogenic Aβ1-42 (Figure 4-3A, B). While previous structural studies used the in vitro 
produced Aβ1-40 polymers101,102 the high-resolution structures of Aβ1-42 amyloids, mostly 
based on solid state NMR have also been reported recently94,95. These structures include 
two molecules per polymer unit, and five β intermolecular sheets spanning residues 2-6 
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(β1), 15-18 (β2), 26-28 (β3), 30-32 (β4), and 39-42 (β5) per each “half” of the fibril (Figure 
4-2, 4-10). The anti-nucleation effects (Figure 4-4A, 4-5B) of substitutions I31P (breaking 
a β4 strand) and F19S as well as F19K (disrupting hydrophobic interactions with the β2 
strand) in the yeast assay are in good agreement with the published structural models 
(Figure 4-10). Likewise, the pro-nucleation effect (Figure 4-4B) of the D23N substitution, 
corresponding to so called “Iowa mutation”, a heritable case of AD72, is also in a good 
agreement with the models. This substitution removes one of negatively charged residues 
presumably facing the solvent that might increase an aggregation propensity.  To confirm 
the previous models that implicate a salt bridge between Asp23 and Lys28, we originally 
hypothesized that the substitution D23K that reverses the charge would knock out 
nucleation as does K28E, while a double substitution D23K, K28E involving a charge 
reversal would restore the salt bridge and thus restore prion nucleation. Though, 
substitution K28E demonstrated an anti-nucleation effect (Figure 4-5A) and the reciprocal 
mutation D23K, K28E restored prion nucleation to a significant extent (Figure 4-5A, 
affecting the β3 strand), D23K in fact increased prion nucleation on its own (Figure 4-5A), 
thus not lending support to the models suggesting the formation of a salt-bridge between 
Asp23 and Lys2895,102.However, our data still demonstrates that residues K28 and D23 
have an important role in the formation of the Aβ (1–42) amyloid fibril and the anti-
nucleation effect of chimera with K28E indeed experimentally verified the latest structural 
models for  Aβ(1–42)95,96.  The solvent-exposed charged residue D23 is  located within 
the sequence segment F19–K28 and has been identified to be of great significance for 
the enhanced toxicity of familial mutations in Aβ(1–40) and shows structural variability with 
typically one or two short β-sheets and likewise, the substitutions D23N or D23K or D23A 
(one of the mutations in A21E, D23A mutant) increased nucleation in our assay, and 
potentially enhances  the stacking of the Aβ molecular out to the next layer along the fibril 
axis and also enables interactions with solvents or chemical agents like metal ions that 
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can stabilize the Aβ fibril by rapidly increasing Aβ aggregation. In the case of substitution 
K28E, the mutation disrupts the hydrophobic interactions with the β2 strand, as 
demonstrated by decreased nucleation (Figure 4-5A). Moreover, a salt bridge has been 
observed between the side chain of K28 and the C terminus of Aβ(1–42) and this fits with 
our data demonstrating decreased nucleation by K28E, potentially disrupting the 
interactions between K28 and the C-terminus (Figure 4-10).  While residues 15–42 are 
packed densely, the N-terminal segment of residues 1–14 is not entirely rigid and has 
been shown by NMR studies to contain Cu coordination mode which involves three 
histidines (His6, His13 and His14)103. His13 is also a crucial residue in the zinc ion-induced 
aggregation of Aβ103. The histidine restudies, specifically His13 coordinate the binding of 
Aβ peptide to metals. H13L, although not reproducing the pro-nucleation effect predicted 
by ArchCandy algorithm in our assay (Figure 4-5B) potentially demonstrates such an 
effect after binding to metal ions that can speed up aggregation and stabilize the Aβ fibril.  
Additionally, the amyloidogenicity score given by ArchCandy are for mutations in Aβ 
peptide and not in the Sup35N-Aβ chimera. Potentially, generating amyloidogenicity 
scores based on the formation of β-arcades in Sup35N-Aβ chimera rather than Aβ peptide 
might work better for the purpose of checking prion nucleation by Aβ mutations using our 
assay since Aβ is physically fused to Sup35N and thus potentially forms a hybrid template 




Figure 4-10. The location of mutations in the 3D structure of Aβ(1–42) fibrils (as per 
ref. 95). The Aβ(1–42) amyloid fibrils is composed of two molecules per subunit, which 
are symmetric with respect to the central axis of the fibril.  The backbone of the two 
symmetric molecules are shown as yellow and orange spines. The 3D structure of the N-
terminal residues 1–14 (dotted yellow lines), the side chains of the positively charged 
residues (red), the negatively charged (blue), the hydrophobic residues (white), and polar 
residues (green). Every second residue is labeled with the one-letter amino acid code. 
The location of mutations on the 3D structure of Aβ(1–42) fibrils are shown as black dotted 
lines. A potential salt bridge between residue K28 and the C-terminus of Aβ(1–42) is 
shown as pink dotted lines.  
The impact of a nucleating construct on spectra of induced [PSI+] “strains”. As explained 
in Chapter 3, Both yeast and mammalian prion and amyloid proteins are known to form 
various variants or “strains” that differ from each other by phenotypic and biochemical 
characteristics and are apparently controlled by distinct protein conformations. Similar to 
the prion strains formed by Sup35N-PrP90-230 derivatives in Chapter 4, we have found 
out that the spectra of [PSI+] strains induced by different Aβ-based chimeric constructs 
also differ from each other (Figure 4-8) either due to the formation of distinct initial nuclei 
by different attached regions of chimeric proteins, followed by an expansion of the amyloid 
region to different regions of the attached Sup35N domain via “deformed templating” 
model92. In this scenario, the spectra of [PSI+] strains might corroborate to the differences 
in the “hybrid” templates formed by the fusion proteins or a preference by Sup35N for 
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certain strain conformations by specific mammalian amyloidogenic proteins physically 
attached to Sup35N.  
Potential applications of the yeast prion nucleation assay – identification of metals that 
influence Aβ nucleation. Initial prion nucleation by mammalian proteins is the crucial step 
triggering the subsequent amyloid formation and pathogenicity of Aβ and potentially other 
disease-related amyloidogenic proteins as demonstrated in Chapter 4. We have used the 
nucleation assay to search for chemical factors and conditions specifically modulating the 
process of initial amyloid nucleation in both a general and a protein-specific manner. Using 
a modified prion nucleation assay, we have screening for both neuronal metal ions that 
can trigger Aβ via dysregulation of brain metal homeostasis104 as well as toxicological 
metal ions104,105 that potentially trigger or accelerate Aβ aggregation by acting as an 
environmental contaminant (Figure 4-9). So far, systematic in vivo information about the 
role of metals in Aβ aggregation is lacking. While Aβ can bind metals, and some metals 
influence Aβ aggregation in vitro, it remains unclear whether or not this occurs at 
concentrations having physiological relevance. Moreover, metals also exhibit broad 
effects on Aβ production and degradation, as well as on the functioning of the human 
organism and brain at various levels. It is therefore unclear if metal effects in AD are 
related to the initial amyloid formation or its consequences. Using physiological 
concentrations of metal ions (150 to 300µM) in non-toxic solvents, we have shown that 
Zn, Li, As, Cd, as well as Cu to an extent significantly increase nucleation by Aβ-based 
chimeric constructs in yeast (Figure 4-9).  While some of these metal ions like As and Cd 
cause toxicity to yeast at high concentrations, they could be tested at lower concentrations 
without causing cytotoxicity. The major problem with the systematic studies of the impact 
of environmental factors on amyloidosis is the lack of rapid experimental assays allowing 
for the detection of potentially amyloidogenic agents through their effects on the initial 
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amyloid formation in living cells. We have developed such an assay that would allow 
identification of true amyloidogenic agents, paving the way for further characterization of 
the molecular mechanisms of their action and determining the potential risks. This may 
pave the way for the development of both therapeutic and prophylactic treatments for 
amyloid diseases that address a triggering mechanism of the disease, initial amyloid 
nucleation. The major advantage of our system in comparison to previously proposed 
yeast-based and cell-based assays is that our assay does not require the chimeric fusion 
protein to propagate a prion state in yeast. Prion detection is achieved by transferring the 
amyloid state to the endogenous yeast Sup35 protein, so that even transient amyloid 
formation by a chimeric construct is then fixed and amplified by conversion of an 
endogenous yeast protein into a prion. Furthermore, non-amyloid multimeric proteins are 
apparently not capable of nucleating prion formation at high efficiency in our system, 
making it possible to use this assay for identifying new potentially amyloidogenic proteins 
or domains, originated from various organisms, including humans. The rapid and easy 
phenotypic detection of prion nucleation in yeast makes our assay amenable to high-
throughput approaches.  
4.5 Conclusions 
• The ability of Aβ1-42, fused to Sup35N, to promote amyloid nucleation in yeast 
was decreased by the removal of two C-terminal amino acids (converting Aβ1-42 
to less amyloidogenic Aβ1-40) 
• A familial pro-AD mutation, D23N increased prion nucleation by Sup35N-Aβ1-42 
in yeast. 
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• Amino acid substitutions K28E or D23K respectively decreased or increased prion 
nucleation by Sup35N-Aβ1-42 in yeast, while a double reciprocal mutation D23K, 
K28E demonstrated prion nucleation comparable to that of Sup35N-Aβ1-42. 
• The ability of Aβ1-42, fused to Sup35N, to promote amyloid nucleation in yeast 
was abolished by amino acid substitutions that alter structural properties of Aβ, 
important for amyloid formation.  
• Sup35N-Aβ1-42 formed SDS-resistant amyloid aggregates and immobilized 
endogenous Sup35 into an aggregated fraction, while Sup35N fused to Aβ1-40 or 
Aβ1-42 triple mutant was unable to do so.  
• Sup35N-Aβ1-42 with different alterations induced different spectra of prion strains 
in yeast 
• Some metal ions suspected to promote AD, increased prion nucleation in the 
presence of Sup35N-Aβ1-42 in the yeast assay. 
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CHAPTER 5. GENERATION AND PROPAGATION OF Aβ- and TAU-DEPENDENT 
PRION STRAINS IN YEAST 
 
This chapter includes the work in preparation for publication and portions of it were 
performed in collaboration with David Lynn and Lary Walker at Emory University. 
 
5.1 Summary 
While previous chapters were dealing with prion nucleation, in Chapter 5 we established 
a yeast model for studying prion propagation by amyloid β (Aβ) or microtubule binding 
protein tau (tau), two human proteins associated with Alzheimer’s disease (AD) in the case 
of Aβ and tau as well as frontotemporal dementia in the case of tau. We have constructed 
chimeric proteins, in which the prion domain (PrD) or an aggregation prone portion of the 
PrD of Sup35 was replaced by human Aβ or the microtubule binding repeat domains of 
human tau and have shown that such a chimeric protein was functional in translational 
termination and could spontaneously switch to the partially non-functional polymeric state, 
thus generating and propagating a prion isoform. The formation of such a prion by Aβ was 
promoted by transfecting yeast cells with in vitro generated Aβ1-42 or Aβ1-40 aggregates. 
Remarkably, the prion isolates formed by the Aβ-based chimeric protein demonstrated 
different phenotypic stringencies, indicating the existence of different Aβ-based prion 
strains, thus mimicking the phenotypic diversity seen in AD.  Thus, our data establishes a 
yeast model for studying Aβ- and tau-dependent propagation of prion strains in yeast and 
provides a unique opportunity for applying high resolution genetic and biochemical 
techniques to studying Aβ or tau strains generated in humans and in vitro. Additionally, 
this model also enables the systematic study of the possibility of a direct cross-seeding of 
tau by Aβ that has not been addressed in cellular models thus far. 
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5.2 Specific materials and methods 
5.2.1 Materials 
5.2.1.1 Strains 
The S. cerevisiae strains used in this study are shown in Appendix Table A. GT2126 was 
constructed by a direct plasmid shuffle (Figure 5-1). The plasmid Aβ1-42-NR-MC with a 
constitutive SUP35 promoter was transformed into GT671 and Sup35 plasmid with a 
LEU2 marker was shuffled out. GT2180 was constructed in a similar manner by using 
GT651 as the donor strain. GT2265 is the MATa derivative of GT2180 and was generated 
by inducing the mating type switch in the presence of plasmid YRpHO106. GT2266 was 
constructed by transforming the Aβ1-42-NR-MC plasmid with a constitutive SUP35 
promoter and a URA3 marker into GT2180 and the Aβ1-42-NR-MC plasmid with a 
constitutive SUP35 promoter and a LEU2 marker was lost. The Sup35MC plasmid with a 
LEU2 marker was transformed into GT2266, and the Sup35MC plasmid with a URA3 
marker was shuffled out by counter selection on 5-FOA media. GT81-1C and GT409 
(Appendix Table A) were employed for the comparisons to [PSI+] strains induced by 
chimeric constructs in SDD-AGE experiments.  
5.2.1.2 Plasmids and primers 
The S. cerevisiae - E. coli shuttle plasmids used in this study and primers used in plasmid 
constructions are shown in Appendix Tables B and C respectively. The chimeric genes 
coding for Aβ-Sup35MC or tau repeat domain (RD) encompassing amino acids 244 to 372 
as well as tau RD with a double point mutations, P301L, V337M, under PCUP1 with a URA3 
marker was constructed by inserting the PCR-amplified BamHI-BglII fragment that codes 
for the region 1-42 of Aβ42 from the plasmids pcDNA3.1(+)-Aβ42 (kindly provided by Dr. 
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K. Ugen, University of South Florida) containing the human Aβ1-42-coding sequence, or 
the repeat domain 244-372 of tau from the plasmids pcDNA3.1(+)-tau-RD-wild-type and 
pcDNA3.1(+)-tau-RD-P301L, V337M mutant (kindly provided by Dr. Marc Diamond, 
Washington University, St. Louis) containing the human tau 244-372-coding sequence, 
into the pmCUP1-Sup35MC vector at the position following the PCUP1 promoter.  
 
Figure 5-1. Scheme of construction of chimera Aβ-MC and tau-MC under the copper-
inducible promoter, PCUP1.  (amino acid positions not to scale). Sup35N terminus or 
“prion domain” is composed of NQ region (rich in asparagine and glutamine) and NR 
region (oligopeptide repeats). The region coding for the prion domain of Sup3N was 
substituted with the region coding for human Aβ1-42 or for human microtubule binding 
repeat domain (RD) of wildtype tau or tau RD with P301L, V337M base substitutions. 
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The chimeric gene coding for Aß42-Sup35NR-MC under a constitutive SUP35 promoter 
with a URA3 marker was constructed in two steps. The first step involved the construction 
of Sup35 plasmid under a constitutive SUP35 promoter in the backbone of a pmCUP1-
based plasmid. This plasmid was constructed via replacing the fragment containing 
SUP35 and the SUP35 promoter in the pRS316 backbone that was excised by using 
restriction endonucleases, XhoI and SacI, with the fragment containing PCUP1 in pmCUP1 
vector. Aß42-Sup35-NR-MC plasmid under a constitutive SUP35 promoter was 
constructed by replacing the SUP35 fragment that codes for the region 1-42 of Sup35 
from the previously constructed Sup35 plasmid in the PCUP1 backbone, with the PCR-
amplified BamHI-PstI fragment containing the Aß42 fragment from the plasmid 
pcDNA3.1(+)-Aβ42 containing the human Aβ1-42-coding sequence.  A Kozak sequence 
followed by an initiating methionine was added to C-terminus of BamHI restriction enzyme 
in the forward oligonucleotide primer (refer primer sequence in Appendix Table C), to 
construct Aβ1-42-containing chimeras. 
 
Figure 5-2. Scheme of construction of chimera Aβ-NR-MC under the endogenous S. 
cerevisiae SUP35 promoter (PSUP35) (amino acid positions not to scale). The region 
coding for the first 42 amino acids of Sup35N was substituted with the region coding for 
human Aβ1-42.  
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Aβ-NR-MC plasmid under the endogenous SUP35 promoter with a LEU2 marker was 
constructed via replacing the XhoI-SacI fragment containing the Aß42-NR-MC and 
constitutive SUP35 promoter from the Aß42-NR-MC plasmid with a URA3 marker and 
inserted into pRS415 vector at the position following the XhoI restriction site.  All the 
regions that underwent PCR amplification as well as immediate flanking regions were 
verified by sequencing, performed at Eurofins MWG Operon (Huntsville, AL). Isolation of 
plasmid DNA from bacteria was performed according to standard procedures. 
5.2.1.3 Antibody  
Sup35C antibody used in this study is described in Chapter 2.    
5.2.1.4 In vitro aggregated Aβ1-42 and Aβ1-40 seeds  
Aβ42 seeds were prepared by Aditi Sharma from Andreas Bommarius Research Lab 
(School of Chemical and Biomolecular Engineering, Georgia Tech) using lyophilized Aβ1-
42 purchased from GenicBio. 1 mg of synthetic Aβ42 was equilibrated to a room 
temperature for at least 30 min in a desiccator. The peptide was resuspended in 1ml of 
NH4OH (10% v/v) to a final concentration of 1mg/ml, followed by incubation at room 
temperature for 10 min. The peptide was sonicated in a sonicator for 5 min and 100µl of 
the solution was aliquoted into ten 1.5ml centrifuge tubes. Small holes were made on the 
lids of the tubes and the tubes were flash frozen in liquid nitrogen and quickly placed in a 
lyophilizer to lyophilize the samples for ~12 hrs., followed by storage at -80°C. To use the 
frozen peptides for conducting experiments, one aliquot was taken out from -80°C and 
resuspended in 50µL of 1mM NaOH and diluted 10-fold with 1M phosphate buffer saline 
(PBS). The protein concentration was measured by Micro Bicinchoninic Acid (microBCA) 
and ensured that the measurement was ~40µM and appropriately diluted as required with 
buffer containing 1µM Thioflavin T. The solution containing Aβ was filtered with 0.2µ filter 
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to remove oligomers or large molecular weight aggregates before use. The Aβ solution 
was pipetted into a 96 well plate and the volume per well was 200µl. The plate was placed 
in a Biotek Synergy H4 Multi-mode plate reader and the fluorescence was measured with 
an excitation wavelength of 440nm and an emission wavelength of 480nm at a 
temperature of 25°C. Readings were recorded every 5-10 min with continuous shaking at 
the medium setting (18Hz frequency, 0.022-inch amplitude). An aggregation cycle was 
approximately completed in 16 hrs. and the aggregates samples were stored in 1.5ml 
centrifuge tubes at -20°C for storage and taken out from the freezer and thawed in ice for 
30 min to be used for the transformation step in the transfection procedure.  
Aβ40 seeds were obtained by continuous shaking of Aβ40 monomers at room 
temperature at 100 rpm. Aβ40 monomers were synthesized using a microwave peptide 
synthesizer (CEM Corporation) by a collaborator, Noel Xiang’ An Li from David Lynn 
Research Lab (Biological Chemistry Department, Emory University). 
5.2.2 Methods 
Standard protocols were used for DNA isolation, gel electrophoresis, restriction digestion, 
gel extraction, ligation, and bacterial transformation68 and are described in Chapter 2. 
Standard yeast media and standard procedures for yeast cultivation, phenotypic analysis, 
and transformation were used and are described in Chapter 2. The schemes and 
description of plasmid shuffle experiments and analysis of colonies are described in the 






5.3.1 Identification and characterization of [Aβ+] strains in yeast 
The S. cerevisiae Sup35 protein can be divided into three major domains as follows: (i) an 
N-proximal prion-forming domain (Sup35N), or PrD, (ii) a middle domain (Sup35M) 
promoting protein solubility and (iii) a C-proximal release factor domain (Sup35C) 
essential for translational termination and cell viability. The Sup35 prion domain is 
composed of three regions: (i) QN-rich region (QN), located before aa position 40, (ii) a 
region of imperfect oligopeptide repeats (NRs) and, (iii) region 97–123 that does not have 
a specific sequence pattern32. In Chapter 3 and 4, we confirmed that transient 
overproduction of a fusion of mammalian amyloid proteins like Aβ1-42 peptide to the C-
terminus of Sup35N fragment promoted the de novo nucleation of [PSI+] in the absence 
of pre-existing prions. pmCUP1-Sup35N-Aβ1-42 also formed SDS-resistant amyloid 
aggregates when analyzed by SDD-AGE, thus confirming Aβ polymerization and 
immobilization of endogenous Sup35 protein in yeast.  
Here, we employed a similar experimental strategy to check if Aβ1-42 can form its own 
prion and propagate various strains in yeast. Previous studies showed that the 
replacement of the Sup35 prion domain (Sup35N) by Aβ4245 causes a termination defect 
and results in protein oligomerization. Thus, this model could not be applied for specifically 
studying Aβ-based strains. To order to do so, Aβ had to be maintained in non-polymerized 
form and switched to the polymerized form in a controlled manner. In this study, we 
reproduced the results obtained previously and employ a modified strategy to switch Aβ 
from a non-polymerized form to a polymerized form to check for the formation of [Aβ+] 
strains generated and propagated by a Aβ-based protein.  
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5.3.1.1 Phenotypic detection of Aβ-MC chimeric protein in yeast 
To develop a yeast model for studying Aβ-dependent prion strains without the prion 
domain of Sup35, a centromeric plasmid with a URA3 marker (Appendix Table A), 
expressing a chimeric protein containing the region coding for Aβ1-42 fused to the N 
terminus of Sup35MC, lacking the prion domain Sup35N, was constructed and placed 
under a copper inducible promoter (PCUP1) (Figure 5-1). Initially, a yeast strain expressing 
only pmCUP1-Aβ-MC was constructed using a plasmid shuffle procedure (Figure 5-3).  A 
S. cerevisiae [psi-] sup35Δ strain with the SUP35 gene on a LEU2 plasmid was 
transformed by URA3 plasmids bearing [Aβ1-42-MC] or [Aβ1-42-NR-MC]. Transformants 
were obtained on medium lacking uracil and leucine (−Ura, Leu) that is selective for both 
plasmids and checked for suppression of the ade1-14 reporter on both medium lacking 
only adenine (−Ade) and medium lacking uracil, leucine, and adenine (−Ura, Leu, Ade). 
These media were used to determine whether the newly introduced Aβ1-42-MC chimeric 
protein is immediately converted into a non-functional form or if it remained functional.  In 
parallel, transformants were streaked out on −Ura medium and replica plated to −Leu 
medium, to identify the Ura+ Leu- colonies that lost the original LEU2 plasmid. Only one 
Ura+ Leu- colony was analyzed from each individual transformant, to ensure 
independence of all colonies from each other.   
 97 
 
Figure 5-3. Construction of the S. cerevisiae strains expressing [Aß-MC] or [Aß-NR-
MC] proteins.  
 To detect [PSI+] formation, we employed the ade1–14 (UGA) reporter. The [psi-] 
strains bearing this reporter are Ade- (i.e. they do not grow on medium lacking adenine) 
and only rarely produce spontaneous Ade+ colonies, in part due to reversions or 
suppressor mutations. The conversion of endogenous Sup35 into a prion form leads to a 
termination defect and read-through of ade1–14, resulting in an Ade+ phenotype. Before 
induction, Aβ-Sup35MC construct, demonstrated nonsense suppression as indicated by 
growth on -Ade (Figure 5-4). This showed that the Sup35MC in the chimera was poorly 
functional in terminating translation, thus resulting in protein polymerization even at 
background levels of expression. After overexpression with 100µM CuSO4, the nonsense 
suppression was not eliminated as demonstrated by growth on -Ade, despite an addition 
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of 100µM CuSO4 to -Ade media to increase the abundance of Sup35MC to improve the 
functionality of the chimera. The control, Sup35MC construct, was functional in terminating 
translation. This confirmed that chimeric Aβ-Sup35MC constructs are partly non-functional 
in termination of translation in yeast.   
 
Figure 5-4. Phenotypic detection of nonsense suppression by Aβ-MC chimeric 
protein. The [psi- pin-] strain simultaneously expressing both Sup35 protein and Aβ-MC 
chimeric protein, do not cause nonsense suppression. After losing [LEU2 SUP35] by 
plasmid shuffle procedure (Figure 5-3), [URA3 Aβ-MC] plasmid without complete Sup35 
is defective in terminating translation and causes nonsense suppression, before or after 
induction with 100µM CuSO4 , despite an addition of 100µM CuSO4  to increase an 
abundance of Aβ-MC protein. 
 
5.3.1.2 Phenotypic analysis of Ade+ colonies formed by Aβ-NR-MC chimeric protein in 
yeast 
The instant polymerization of Aβ-Sup35MC construct made the controlled formation of Aβ-
dependent prion strains impossible. To circumvent this, we constructed another plasmid 
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in which only the QN-rich region encompassing the first 42 amino acids of Sup35N is 
replaced by Aβ42, while retaining region of oligopeptide repeats (NRs) in Sup35N region 
and placed under the PSUP35 constitutive promoter (Figure. 5-2). pmSUP35-Aβ-NR-MC 
plasmid and a control, pmCUP1-Sup35MC plasmid were simultaneously transformed into 
[psi- pin-] strain GT671 with genomic SUP35 gene deleted, and bearing a Sup35-
expressing plasmid (pASB2, with the LEU2 marker).  Then, the original Sup35-expressing 
plasmid was lost from the strain by counter selecting on –Ura and –Leu media.  Next, 8 
individual colonies bearing only the PSUP35-Aβ-NR-MC plasmid were patched on -Ura and 
replica plated to –Ade media to check for nonsense suppression. The chimeric protein 
was completely functional in terminating translation as indicated by a lack of growth on -
Ade, similar to the control PSUP35-MC plasmid (Figure 5-5A).  After an incubation period of 
20 days, all the patches produced Ade+ papillae (Figure. 5-5A and Table 5-1).  The de 
novo-formed Ade+ papillae were individually picked from the original -Ura plate and 
streaked on to complete YPD medium to check for color and -Ade medium to check for 
growth. The Ade+ isolates produced colonies of different phenotypic stringencies and 
different levels of growth on YPD and -Ade respectively. The Ade+ colonies were divided 
into three groups designated as “strong”, “intermediate” and “weak” strains based on 
growth on –Ade medium and color on YPD medium (Figure 5-5B and Table 5-1). The vast 
majority of Ade+ colonies induced by the Aβ-based chimeric construct were curable by 
serial passages on medium containing an antiprion agent guanidine hydrochloride, 
GuHCl. This indicated that the GuHCl-curable nonsense suppression state was stably 
maintained by daughter cells.   
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Figure 5-5. Phenotypic detection of Ade+ colonies formed by Aβ-NR-MC chimeric 
protein. A - The [psi- pin-] strain simultaneously expressing both Sup35 protein and Aβ-
NR-MC chimeric protein remains functional in terminating translation. After losing [LEU2 
SUP35] by plasmid shuffle procedure (Figure 5-3), the Aβ-NR-MC chimeric protein confers 
an Ade-  phenotype after 10 days (“Short incubation”), indicating full functionality.   After 
an incubation period of 20 days (“Long incubation”), [URA3 Aβ-NR-MC] spontaneously 
forms Ade+ colonies. B – The colony purified Ade+ papillae exhibited different phenotypic 
stringencies and lost the ability to grow on –Ade medium after 20-40 generations in the 
presence of guanidine hydrochloride (GuHCl), an agent antagonizing propagation of yeast 
prions. 






















Strong 3 4 7 
Intermediate 11 2 13 




Strong 3 8 11 
Intermediate 13 5 18 
Weak 8 2 10 
 
Total  47 23 70 
 101 
5.3.1.3 Biochemical characterization of Ade+ colonies by Aβ-Sup35NR-MC chimeric 
protein 
Three representative Ade+ colonies generated by Aβ-Sup35NR-MC chimeric protein that 
had different phenotypic stringencies, namely strong, intermediate, and weak, including 
an Ade- control containing Aβ-Sup35NR-MC, and the Ade+ isolate with an intermediate 
phenotypic stringency that was cured with 5mM GuHCl, were analyzed using semi-
denaturing detergent agarose gel electrophoresis69 (SDD-AGE) as described in Chapter 
2. The weak and intermediate Ade+ isolates containing Aβ-Sup35NR-MC produced 
detergent-resistant polymers in the yeast cells (Figure 5-4) as is typical of yeast prions 
and amyloids and promoted the immobilization of endogenous Sup35 protein into an 
aggregated fraction. The strong Ade+ isolate could not be detected, and interestingly it was 
proven later by direct plasmid shuffle, discussed further in this chapter, that this isolate is 
not dependent on Aβ-Sup35NR-MC (data not shown). The cured version of the Ade+ 
isolate with an intermediate phenotypic stringency migrated as monomers through the gel, 





Figure 5-6. Biochemical characterization of Ade+ isolates generated in the presence 
of Aβ-Sup35NR-MC. The representative Ade+ isolates of different stringencies (weak, 
strong and intermediate – lanes 3, 4 and 6, respectively), as well as control strains, GT81-
1C, [PSI+] (lane 1) and GT409, [psi-] (lane 2) strains, the original Ade- ([aβ-]) strain (lane 
5), and a GuHCl-cured derivative of the intermediate Ade+ isolate (lane 7, from a different 
gel) were analyzed by semi-denaturing detergent agarose gel electrophoresis (SDD-AGE) 
followed by the reaction to the Sup35C-specific antibody. Positions of monomers and 
detergent-resistant polymers are indicated. The strong Ade+ isolate used in this 
experiment was later identified as a false potential (see below, Fig 5-10 and Table 5-3).  
 
5.3.1.4 Generation of [Aβ+] strains in yeast by transfection with in vitro produced Aβ 
amyloids 
So far, the phenotypic properties of the Ade+ isolates generated spontaneously by Aβ-NR-
MC chimeric protein have been characterized.  In the case of prion proteins, phenotypic 
manifestation of the strain-specific patterns is achieved via interactions between the 
chimeric protein and the cellular machinery, but the molecular differences underlying these 
patterns are controlled by the prion protein itself. To provide a strong support for a 
mechanism of protein-only templating, it was checked if [Aβ42-NR-MC] could maintain 
and propagate a prion pattern if synthetically seeded Aβ42 or Aβ40 aggregates were 
added to it. To do this, the yeast transfection protocol was performed107 using the materials 
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described in materials methods section, 5-2-2 and as illustrated in Fig 5-7A. The yeast 
cells carrying [URA3 Aβ-NR-MC] plasmid was transfected with Aβ42 or Aβ40 aggregates 
and transfectants were patched on -Ura medium, along with the colonies obtained in the 
strain that was not transfected with any aggregates, and replica plated to -Ade to check 
for growth. Only the yeast cells transfected with Aβ42 aggregates grow on -Ade (Figure 
5-7B and Table 5-2). Colony purification of the Ade+ papillae from the original -Ura plate 
containing the transfectants on YPD media demonstrated the formation of Ade+ colonies 
of different phenotypic stringencies and they showed different levels of growth on -Ade 
media. (Figure 5-7C). The Ade+ colonies from were divided into three groups designated 
as “strong”, “intermediate” and “weak” strains based on growth on –Ade medium and color 
on YPD medium. The vast majority of Ade+ colonies induced by the Aβ-based chimeric 
construct were curable by serial passages on medium containing GuHCl, thus confirming 
that the GuHCl-curable nonsense suppression state was stably maintained by daughter 
cells (Figure 5-5C, Table 5-2). This result was consistent with what was obtained with 
spontaneous formed Ade+ colonies. 
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Figure 5-7. Generation of Ade+ colonies after transfection of Aß aggregates into 
yeast. A- Summary of transfection procedure. B - Representative Ade+ transfectants 
obtained after Aß42 or Aß42 aggregates were transfected into a [psi-] strain carrying 
[URA3 Aβ-NR-MC] plasmid. Yeast cells were grown on –Ade medium (for suppression 
assay) at 30°C for 8 days. The Ade+ transfectants, after colony purification, exhibited 
different phenotypic stringencies. These derivatives lost the ability to grow on –Ade 
medium after 20-40 generations in the presence of GuHCl (refer Table 5-1) . Yeast cells 
were grown on YPD (for color assay) and on –Ade medium (for suppression assay) at 





Table 5-2. Summary of a proportion of Ade+ colonies generated by Aβ-NR-MC after 
different transfection experiments 





























Aβ42 I 30 2 2 1 5 
 II 21 2 3 3 8 
 III 159 14 28 24 66 
Total (for Aβ42) 210 18 33 28 79 
Aβ40 I 31 4 3 2 9 
 
Control I 16 0 0 0 0 
 II 21 0 0 0 0 
 III 105 0 0 0 0 
 
Total (for control) 142 0 0 0 0 
 
5.3.1.5 Phenotypic characterization and identification of [Aβ+] strains in yeast 
To eliminate the possibility that the Ade+ colonies generated spontaneously or by 
transfection is dependent on Sup35MC region which codes for a major portion of the Aβ-
NR-MC chimera, or if the Ade+ colonies are maintained with the help of a nuclear element 
or cellular machinery in yeast, a series of plasmid shuffles were made to replace [URA3 
Aβ-NR-MC] plasmid with a different plasmid bearing pmSUP35-Aβ-NR-MC, to check if the 
Ade+ phenotype was not changed with a different plasmid. To do this, a direct plasmid 
shuffle (Figure 5-6) was performed. The Ade+ isolates  generated by [URA3 Aβ-NR-MC] 
plasmid, either spontaneously or via transfection, was either - a) transformed with [LEU2 
Aβ-NR-MC] or a control [LEU2 MC] plasmid or b) mated with a Ade-  strain carrying [LEU2 
Aβ-NR-MC] or a control [LEU2 MC] plasmid and containing an opposite mating type and 
was isogenic to the strain with the Ade+ isolates carrying [LEU2 SUP35-Aβ-NR-MC]. The 
resulting haploid (in the case of transformation) or diploid (in the case of mating) was 
selected on -Ura-Leu-Ade. The [URA3 Aβ-NR-MC] plasmid was shuffled out by 
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counterselection on 5-FOA medium. 3 individual Ade+ isolates per plasmid combination 
was checked on -Ade for nonsense suppression (Fig 5-6). If the  nonsense suppression 
by the Ade+ isolates could be maintained in the presence [LEU2 Aβ-NR-MC] before and 
after the loss of  [LEU2 Aβ-NR-MC]; and if the nonsense suppression by the Ade+ isolates 
was eliminated when the Ade+ isolates was introduced with [LEU2 SUP35-MC] before and 
after the loss of [URA3 Aβ-NR-MC], then that particular Ade+ isolate was considered a 
[Aβ+] potential and was further characterized by reverse plasmid shuffle. The Ade+ isolates 
that demonstrated growth in both the presence of [LEU2 Aβ-NR-MC] or [LEU2 SUP35 
MC] was eliminated as a false [Aβ+] potential and was confirmed to not be maintained by 
[Aβ-NR-MC].  
 




Direct plasmid shuffle (STEP I) 
As per the procedure (Figure 5-6) and outcomes described above, the Ade+ isolates from 
spontaneous and transfection experiments (Figures 5-3, 5-5, Table 5-4, 5-5), underwent 
a direct plasmid shuffle to replace [URA3 Aβ-NR-MC] with [LEU2 Aβ-NR-MC] or [LEU2 
MC]. Two Ade+ isolates, each representative of a [Aβ+] potential and a false [Aβ+] potential 
is shown (Figure 5-8, STEP I).  Ade- isolate carrying [URA3 Aβ-NR-MC] was used as a 
control. In Step I, Ade+  isolates 1 and 2 carrying [URA3 Aβ-NR-MC] could co-exist with 
[LEU2 Aβ-NR-MC] as demonstrated by growth on -Ura-Leu-Ade, indicating that the Ade+ 
phenotype could be maintained. However, Ade+ isolate 1 with [URA3 Aβ-NR-MC] and 
[LEU2 MC] also demonstrated growth on -Ura-Leu-Ade, indicating that this isolate is not 
controlled by [Aβ-NR-MC], unlike isolate 2 in which the presence of both [URA3 Aβ-NR-
MC] and [LEU2 MC], could not maintain the Ade+ phenotype. The Ade-  control could not 
grow in the presence of any plasmid as it did not possess an Ade+ phenotype to begin 
with.  
Direct plasmid shuffle (STEP II) 
After the loss of [URA3 Aβ-NR-MC] (Figure 5-6), Ade+ isolates 1 could retain nonsense 
suppression in the presence of both [LEU2 SUP35- Aβ-NR-MC] or [LEU2 MC], thus 
indicating that this isolate demonstrated a prion-like phenotype, that is not maintained only 
by [Aβ-NR-MC] and is not characterized further. Ade+ isolates 2 could retain nonsense 
suppression only in the presence of both [LEU2 SUP35- Aβ-NR-MC] and not [LEU2 MC], 
thus indicating that this isolate demonstrated a prion-like phenotype that is maintained 
only by [Aβ-NR-MC] and is further characterized by reverse shuffle.  
The dependence or independence of Sup35MC region for [Aβ+] propagation. [Aβ+] 
potentials among the Ade+ isolates generated by Aβ-NR-MC chimera that could be 
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maintained exclusively by Aβ-NR-MC were successfully obtained. While the isolates 
generated by Aβ-NR-MC chimera could be maintained by [Aβ-NR-MC], an important step 
was to ensure that the Ade+ phenotype could not be maintained by [MC], and thus be 
restored when the original inducer plasmid, [LEU2 Aβ-NR-MC], was reintroduced to the 
isolates. To confirm this, it had to be demonstrated that [Aβ+] potentials from STEP II that 
were transformed with [LEU2 Aß-NR-MC] could maintain the Ade+ phenotype after a 
reintroduction of the original [URA3 Aß-NR-MC]. Also, the [Aβ+] potentials from STEP II 
that were transformed via shuffle with [LEU2 MC] should not be able to maintain the Ade+ 
phenotype after a reintroduction of the original [URA3 Aß-NR-MC],   
 
Figure 5-9. Analysis of Ade+ potentials by reverse plasmid shuffle. 
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Reverse plasmid shuffle (STEP III) 
The [Aβ+] potential (isolate 2 in this case) containing strains from STEP II carrying [LEU2 
Aβ-NR-MC] plasmid or control [LEU2 MC] plasmid, were reintroduced with [URA3 Aβ-NR-
MC] plasmid or control [URA3 MC] plasmid by transformation, and their phenotypes were 
checked by growth on -Ura-Leu-Ade. The Ade+ phenotype could be maintained by the 
isolate 2 (representative of [Aβ+]) with [LEU2 Aβ-NR-MC] after the reintroduction of [URA3 
Aβ-NR-MC] as demonstrated by growth on -Ura-Leu-Ade. As expected, the isolate 2 with 
[LEU2 MC] that was transformed with [LEU2 Aβ-NR-MC] or control [LEU2 MC], could not 
produce an Ade+ phenotype, as demonstrated by a lack of growth on -Ura-Leu-Ade for 
both combinations. This was a preliminary confirmation that [MC] could not maintain the 
Ade+ phenotype generated by [URA3 Aβ-NR-MC] and as a result, cannot transmit the 
amyloid template to [LEU2 Aβ-NR-MC].  
Reverse plasmid shuffle (STEP IV) 
After the loss of [LEU2 Aβ-NR-MC] or [LEU2 MC] via reverse plasmid shuffle (Figure 5-
7), the phenotypes of Ade+ isolates with [URA3 Aβ-NR-MC] or [URA3 MC] was checked 
on -Ade. Ade+ Isolate 2 with [URA3 Aβ-NR-MC] demonstrated nonsense suppression, as 
indicated by growth on -Ade. The Ade-  and Ade+ versions of Isolate 2 with [URA3 MC] 
could not grow on -Ade. This definitively confirmed that the Ade+ phenotype generated by 
[URA3 Aβ-NR-MC] could transmit a prion-like state to [LEU2 Aβ-NR-MC] and propagate 
the same in yeast. This was evidenced by the maintenance of the prion state after the 
reintroduction of the [URA3 Aβ-NR-MC] (originally used for spontaneous formation and 
transfection experiments), followed by a loss of the intermediate [LEU2 Aβ-NR-MC]. 
Additionally, the Ade+ phenotype generated by [URA3 Aβ-NR-MC] could not be transferred 
to [LEU2 MC] and thus, could not be propagated in yeast after a reintroduction of the 
 110 
[URA3 Aβ-NR-MC] plasmid. The potentials that were obtained after analysis by direct and 
reverse shuffles were termed as [Aβ+], denoting that these isolates are generated and 
propagated by Aβ-NR-MC chimeric protein. All the Ade+ isolates obtained from 
spontaneous formation and transfection experiments were verified by direct and reverse 
plasmid shuffles, and the proportion of Ade+ isolates/[Aβ+] potentials that demonstrated 
different strain stringencies as per their color on YPD were also recorded (Table 5-6, 5-7)  
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Figure 5-10. Analysis of Ade+ isolate 2 by direct and reverse plasmid shuffle. (Steps 
I and II) - A representative of an Ade+ isolate, formed spontaneously or via transfection, 
that produced a false [Aß+] potential and a [Aß+] potential is shown. The Ade+ isolates 
including an Ade- control was introduced with [LEU2 Aß-NR-MC] or [LEU2 MC] and 
underwent a direct plasmid shuffle to lose [URA3 Aß-NR-MC]. The Ade+ phenotype could 
be maintained by Ade+ isolate 2. (Steps III and IV) Ade+ isolate 2 was reintroduced with 
[URA3 Aß-NR-MC] or [URA3 MC] and went through reverse shuffle to lose [LEU2 Aß-NR-
MC] or [LEU2 MC]. The Ade+ phenotype could be maintained by [URA3 Aß-NR-MC] but 
not by [URA3 MC]. 
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Number of Ade+ colonies 
analyzed by direct shuffle 
 
  False          [Aβ+]       Total 
  [Aβ+]        potential    Ade+ 
potential                     tested 
 







Strong 1 0 1 0 
Intermediate 0 1 1 1 
Weak 0 1 1 1 




Strong 8 9 17 9 
Intermediate 4 27 31 25 
Weak 1 17 18 17 
 Total 13 53 66 51 
Total 14 55 69 53 
 
5.3.2 Identification of prion-like phenotype generated by human tau peptide in yeast 
The neuronal inclusions of Alzheimer’s disease are made of the microtubule-
associated protein tau, in a hyperphosphorylated state50,51. Abundant filamentous tau 
inclusions are not limited to Alzheimer’s disease. They are the defining neuropathological 
characteristic of frontotemporal dementias as well. However, to the best of our knowledge, 
there are no yeast model for amyloid formation and propagation by tau. In section 5-3-1, 
we confirmed that the replacement of the Sup35 prion domain (Sup35N) by Aβ42 caused 
a termination defect and results in protein oligomerization. Thus, this model could not be 
applied for specifically studying Aβ-based strains as Aβ had to be maintained in non-
polymerized form and switched to the polymerized form in a controlled manner. However, 
the repeat domain of tau is not as amyloidogenic as Aβ and thus we used the approach 
of replacing the Sup35 prion domain (Sup35N) by a wildtype and mutant version of tau 
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repeat domain (RD) (Figure 5-1) to establish a yeast model for the formation of tau-
dependent phenotypically detectable prion.   
5.3.2.1 Expression of chimeric constructs containing wild-type or mutant tau fused to 
Sup35MC in yeast 
We have also constructed the chimeric version of the yeast Sup35 protein, tau(WT)-MC, 
in which the whole Sup35N region was replaced by the repeat domain (RD) of tau 
encompassing amino acid positions from 244 to 372 (Figure 5-1). Tau mutations in familial 
frontotemporal dementia and parkinsonism linked to chromosome 1751 (FTDP-17) are 
missense mutations that are located in the microtubule-binding RD or close to it. In 
addition to tau(WT)-MC, we have also constructed a version of tau-MC construct named 
as tau(Mut)-MC, containing two missense mutations, P301L and V337M, in exon 9 and 
exon 10 respectively. Both these constructs were placed under the control of the copper-
inducible yeast promoter (PCUP1). Initially, a yeast strain expressing only pmCUP1-
tau(WT)-MC or pmCUP1-tau(Mut)-MC was constructed using a plasmid shuffle procedure 
used for constructing pmCUP1-Aβ-MC (Figure 5-3).  A S. cerevisiae [psi-] sup35Δ strain 
with the SUP35 gene on a LEU2 plasmid was transformed by URA3 plasmids bearing 
[tau(WT)-MC] or [tau(Mut)-MC] as well as a control, [MC]. Transformants were obtained 
on medium lacking uracil and leucine (−Ura, Leu) that is selective for both plasmids and 
checked for suppression of the ade1-14 reporter on both medium lacking only adenine 
(−Ade) and medium lacking uracil, leucine, and adenine (−Ura, Leu, Ade). These media 
were used to determine whether the newly introduced tau-MC chimeric proteins were 
immediately converted into a non-functional form or if it remained functional.  In parallel, 
transformants were streaked out on −Ura medium and replica plated to −Leu medium, to 
identify the Ura+ Leu- colonies that lost the original LEU2 plasmid. Only one Ura+ Leu- 
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colony was analyzed from each individual transformant, to ensure independence of all 
colonies from each other.   
5.3.2.2 Phenotypic detection of Ade+ colonies formed by tau-based chimeric proteins in 
yeast 
Replacement of Sup35N by tau(WT) or tau(Mut) slightly decreased functionality of Sup35 
in translation termination, leading to growth of cells containing tau(WT)-MC as well as tau 
(Mut)-MC (without complete Sup35) on –Ura-Leu-Ade medium at background 
concentrations (3 µm) of CuSO4. However, growth on –Ura-Leu-Ade was eliminated by 
addition of 10 µm of CuSO4, apparently due to increase in tau(WT)-MC abundance (Figure 
5-11A). After the loss of LEU2 Sup35, a transient increase in tau(WT)-MC or tau(Mut)-MC 
levels on the medium with 100 µm CuSO4 lead to formation of Ade+ papillae capable of 
growing on –Ade medium with 10 µm CuSO4 (Figure 5-11B). Moreover, the tau(Mut)-MC 
construct previously shown to promote tau aggregation in the mammalian cell models, 
produced Ade+ prion derivatives with higher frequency compared to tau(WT)-MC (Figure 
5-11B). This Ade+ phenotype formed by tau(WT)-MC (data not shown) and tau(Mut)-MC 
was heritable in mitotic divisions and curable by GuHCl, thus manifesting itself as a prion 
(Figure 5-11C). Cell lysates from strains with tau(Mut)-MC, before and after transient 
induction with 100 µm CuSO4 , were analyzed using semi-denaturing detergent agarose 
gel electrophoresis (SDD-AGE) as described in Chapter 2. Tau(Mut)-MC induced with 100 
µm CuSO4 produced detergent-resistant polymers in the yeast cells (Figure 5-4D) as is 
typical of yeast prions and amyloids and promoted the immobilization of endogenous 




Figure 5-11. Phenotypic detection of Ade+ phenotype formed by tau-MC chimeras. 
(A) The [psi- pin-] strain expressing both Sup35 protein and tau-MC chimeric proteins were 
more functional in terminating translation in the presence of 10µM CuSO4. After losing 
[LEU2 SUP35] by plasmid shuffle procedure, a transient increase in tau-MC levels on the 
medium with 100 µm CuSO4 lead to formation of Ade+ papillae capable of growing on –
Ade medium with 10 µm of CuSO4 after 10 days of incubation (B) The colony purified Ade+ 
papillae from mutated tau(Mut)-MC exhibited different phenotypic stringencies and lost the 
ability to grow on –Ade medium in the presence of GuHCl. (C) For biochemical 
characterization, cell lysates from strains expressing tau(Mut)-MC before and after 
transient induction with 100 µm of CuSO4 was analyzed by SDD-AGE followed by the 
reaction to the Sup35C-specific antibody.  
 
5.4 Discussion 
Prion formation by Aβ and tau in yeast independent of Sup35N or Sup35Q/N-domains in 
yeast. Previous studies45 and our data (Figure 5-4), chimeric Aβ-Sup35 constructs 
containing Aβ42 instead of the whole Sup35N region are partly non-functional in 
termination of translation, apparently because they instantly form polymers in yeast, 
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making a switch between the non-amyloid and amyloid states, and controlled formation of 
Aβ-dependent prion strains, impossible. We found that the repeat domain of tau fused to 
Sup35MC could be retained in a functional state in the presence of continuous 
overproduction of the chimeric protein to increase the levels of Sup35MC (Figure 5-11). 
The non-functionality Aβ-MC can be attributed either to the highly amyloidogenic nature 
of Aβ42 causing cellular toxicity and resulting in instant aggregation or due to lack of the 
Sup35N portion including a region of oligopeptide repeats (NRs, Figure 5-2), which is 
implicated in interactions with the chaperone machinery, composed of the Hsp104, Hsp70 
and Hsp40 proteins and is required for the fragmentation of Sup35 prion aggregates. We 
have shown that the replacement of Aβ with the Q/N rich aggregation prone domain of 
Sup35 could be maintained in a functional form (Figure 5-5). The resulting chimeric protein 
was expected to nucleate a prion more efficiently than other models53,54 as well as fusions 
to Sup35C, due to the high amyloidogenicity of Aβ and due to the presence of OR region 
of Sup35 that is essential for prion propagation, thus enabling the study of Aβ- and tau-
based prion nucleation and propagation in yeast.  
 Aβ-NR-MC and tau-MC chimeric (wildtype and mutant) chimeric proteins, while 
functional, could switch to a prion form and cause nonsense suppression, in the absence 
of the aggregation-prone Q/N domain of Sup35 in the case of Aβ (Figure 5-5A) or the prion 
domain of Sup35 in the case of tau (Figure 5-11). The Ade+ phenotypes of different 
stringencies by Aβ-NR-MC and tau-MC chimeric proteins could also be propagated to 
daughter cells after many generations and cured by the prion-eliminating agent GuHCl, 
thus following a non-Mendelian pattern of inheritance, like yeast prion proteins32 (Figure 
5-5B, 5-11, and Table 5-1).  
Formation of Aβ-dependent strains after transfection with Aβ1-42 or Aβ1-40 aggregates. 
The “transfection” process32,107 differs from spontaneous formation of prion isolates by an 
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introduction of a pre-formed aggregate, reflecting characteristic of unique conditions of its 
induction environment. Typically, in the same species, the phenotype of a particular prion 
template or variant is expected to be faithfully perpetuated in a recipient protein of the 
same or similar sequence. However, transfection of prion material into a new species may 
cause the transfected prion to exhibit a phenotype unlike spontaneously formed prion in 
the same cell environment. This may occur even though the recipient strain expresses the 
same protein. Transfection, thus, becomes a valuable tool, giving us the ability to examine 
one and the same prion variant in different cellular backgrounds, providing insight into the 
effects of the cell environment on prion maintenance and propagation of prion strains.  
Aβ1-42 or Aβ1-40 aggregates following transfection into yeast carrying Aβ-NR-MC 
chimeric protein could generate different [Aβ+] strains, as detected on YPD color assay 
and -Ade suppression assay (Figure 5-7, 5-12, and Table 5-2).  
Role of Sup35MC in [Aβ+] and potentially [TAU+] strain propagation. For Aβ, the 
plasmid shuffle results (Figure 5-10, Table 5-3) confirmed that a majority of Ade+ potentials 
formed by Aβ-NR-MC chimeric protein via spontaneous formation or by transfection, later 
verified to be [Aβ+], were maintained and propagated in strains expressing only Aβ-NR-
MC and not by Sup35MC (or Sup35C – data not shown), indicating that [Aβ+] formation 
and propagation is primarily driven either by Aβ or Aβ-NR. The small majority that was not 
dependent on Aβ-NR-MC for the Ade+ phenotype could be due to the formation of [MCS+] 
(data not published, refer Meng Sun Thesis in Georgia Tech repository), a prion-like state 
caused by Sup35MC in the absence of the prion domain of Sup35.  Unlike [Aβ+], [MCS+] 
followed a Mendelian pattern of inheritance, indicating the involvement of a nuclear 
element indicating that the prion-like factor and a nuclear factor can co-exist, and both 
may contribute to [MCS+]. This makes it crucial to analyze all the colonies obtained either 
spontaneously or by transfection with direct and reverse shuffles to eliminate the 
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possibility of prion-like states like [MCS+]. In a study108 where a wild-type aggregation-
prone protein, human heterogeneous nuclear ribonucleoprotein, hnRNPA2-Sup35 fusion 
was employed as the sole copy of Sup35, it remains to be understood if the Ade+ 
phenotype is a result hnRNPA2B1 or due to the formation of another prion/nuclear factor 
that is contributing towards the prion phenotype, making a detailed characterization of the 
prion phenotypes crucial.  
Impact of Aβ and tau on spectra of induced [Aβ+] and potentially [TAU+] strains.  Both 
yeast and mammalian prion and amyloid proteins are known to form various variants or 
“strains” that differ from each other by phenotypic and biochemical characteristics and are 
apparently controlled by distinct protein conformations. In the case of [PSI+], strains can 
differ from each other in the stringency of termination defect, mitotic stability, aggregate 
size, fragmentation by chaperones etc. We have shown that Aβ-NR-MC and tau-MC 
chimeric proteins can also induce a spectra of prion variants in yeast. It has also been 
suggested that the oligopeptide repeats facilitate prion fragmentation by Hsp10441 either 
by providing a binding site for Hsp104 or by changing the conformation of the amyloid fiber 
core to allow Hsp104 to bind to it. Interestingly, a higher proportion of intermediate and 
weak [Aβ+] strains were generated compared to strong [Aβ+] strains by spontaneous 
formation as well as transfection (Table 5-2, 5-3). This is consistent with the fact that 
stronger prion strains are mitotically less stable than weak and intermediate prion strains 
and thus, are efficiently fragmentated by the cellular machinery32 composed of Hsp104 
and its partners whereas the other variants are more stable and thus allow a monomer 
addition to the prion fiber, thus propagating the prion variant in a more controlled and 
stable fashion. Alternatively, the prion fiber formed by intermediate and weak [Aβ+] strains 
could be compositionally different compared to the stronger [Aβ+] strains92. A possible 
explanation for the formation of [Aβ+] variants is the formation of distinct initial nuclei by 
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Aβ as explained in Chapters 3 and 4 for prion nucleation by mammalian proteins, followed 
by an expansion of the amyloid region to the attached Sup35NR-MC domain. Depending 
on the amyloid template formed by Aβ-NR-MC chimera, it can be hypothesized that 
Hsp104 binding to the amyloid core and the resulting fragmentation would vary, thus 
producing different strains. 
5.5 Conclusions 
• Chimeric proteins, Aβ-NR-MC or tau-MC, in which the aggregation domain of 
Sup35 was substituted by either Aβ1-42 or tau244-372 (Wildtype or with mutations 
P301L, V337M), were functional in translation termination and could 
spontaneously convert into a partly non-functional prion state.   
• Formation of detergent-resistant aggregates by the chimeric Aβ-NR-MC or tau-MC 
proteins in a prion state were confirmed by a biochemical approach. 
• Propagation of prion strains produced by Aβ-NR-MC protein depended entirely on 
the Aβ-NR region, as these strains are not propagated by Sup35MC (or C)  
• Transfection with in vitro produced Aβ1-40 or Aβ1-42 amyloids induced a 










• Fusion of mammalian amyloidogenic proteins to the prion domain of a yeast 
protein Sup35 nucleated a prion in yeast in the absence of pre-existing prions. 
• Fusion of multimerization-prone non-amyloidogenic proteins to the prion domain 
of Sup35 could not nucleate [PSI+] 
• The amyloidogenic patterns of a mammalian protein drove the prion formation 
and propagation in the yeast model. 
• The effects of alterations in human Amyloid beta (Aβ1-42) peptide associated 
with Alzheimer’s disease (AD) fused to Sup35N to promote amyloid nucleation in 
yeast showed a similar trend to in vitro studies and structural models for Aβ1-42 
• A small-scale chemical screen identified metal ions that could promote amyloid 
nucleation by Aβ1-42 fused to Sup35N. 
• Human Aβ peptide associated with AD as well as the wild-type and mutated 
repeat domain (RD) of human tau protein, associated with AD and frontotemporal 
dementia, generated and propagated a polymeric prion state in yeast, when 
substituted for the aggregation-prone region of the yeast protein Sup35.  
• In vitro produced Aβ polymers converted an Aβ-based chimeric protein into a 
polymeric state after transfection into yeast. 
• Aβ- and tau-based chimeric proteins propagated distinct prion strains in the yeast 





IMPACT AND FUTURE PERSPECTIVES 
 
The results present in this work highlight the contribution of amyloid/prion properties of 
mammalian amyloidogenic proteins to drive the initial nucleation and propagation of prion 
strains in yeast. The significance of this work is the development of sensitive and selective 
systems that produce a phenotypic output that can be easily detected in yeast. 
Additionally, non-amyloidogenic multimer forming proteins can eliminated as false 
positives using the same system.  
In Chapters 3 and 4, amyloidogenic proteins that could nucleate a prion in yeast were 
identified and the prion properties of one such protein, Amyloid beta, was explored in 
detail. An interesting finding from the same is the promotion of prion by an amyloidogenic 
portion of myocilin peptide composed of a very short stretch of amino acids that previously 
produced amyloid polymers in vitro in the lab of our collaborator, Dr. Raquel Lieberman. 
Myocilin is not a well-established amyloid and the only evidence for its amyloid properties 
are from in vitro experiments. Our work is the first line of evidence for prion properties of 
myocilin in a cell-based model. Recent studies related to Alzheimer’s disease (AD), point 
towards tau, an amyloidogenic protein studied in Chapter 5, as the main culprit in AD 
pathology and in fact, a new data mining analysis done on 51 independent multiple mice 
models of AD correlate with phosphorylated tau as the main cause for cognitive decline in 
AD, potentially exacerbated by Amyloid beta. Prion nucleation experiments using different 
isoforms of tau that have been shown to have pro- and anti-aggregation properties in 
animal models or in vitro will be performed to identify sequences that influence prion 
nucleation in yeast. To model phosphorylated tau in yeast, the kinases - Mds1 and Pho85 
which are the functional yeast orthologues of mammalian Gsk-3β and Cdk5 whose 
deletion has been previously shown to cause an increased phosphorylation of tau, will be 
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used. In addition to known and lesser known amyloidogenic proteins, novel proteins with 
different levels of amyloidogenicity can also be studied for their amyloid/prion properties 
in yeast. 
In Chapter 5, a system was developed to identify and characterize amyloidogenic proteins 
that could propagate prion strains on their own in yeast. Amyloid beta and different 
isoforms of tau faithfully formed and propagated prion strains in yeast. Till date, there are 
no yeast models that can effectively monitor the propagation of strains by amyloidogenic 
proteins in yeast, especially via transfection with amyloid polymers. One of the main and 
an unexplored drawback in treating amyloid diseases is potentially, the existence of 
different variants and a lack of understanding and detection of the specific variant that is 
being treated. This is certainly the case for diseases caused by PrP but increasing 
evidence in the field of amyloid biology does not exclude the possibility of this being the 
case for certain amyloid diseases caused by proteins with transmissible properties. This 
opens an array of opportunities to study prion propagation using the model developed in 
our work. As a follow-up to the collaborative work with research groups at Emory as 
demonstrated in Chapter 5, the system we have developed will be employed to study the 
propagation of prion strains in yeast after transfection with seeded Aβ40 or Aβ42 extracts 
as well as extracts from the brains of AD and non-demented patients with amyloid plaques. 
This will provide us with an understanding if the prion template in each strain is faithfully 
propagated or if they undergo some kind of selection to propagate a different spectra of 
prion strains, taking into consideration the cellular environment of yeast. Another 
interesting scientific question that can potentially be immediately addressed due to 
resource availability is to use our system to check for self-seeding of tau using tau-MC 
chimeric proteins by seeded and unseeded tau amyloid extracts as well as to check for 
cross-seeding of tau by Aβ amyloid extracts including the ones extracted from the brains 
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of AD and non-AD patients, to evaluate the propagation of tau-based prions strains and if 
indeed, there is a cross-talk between the proteins involved in AD. If there is a pattern that 
shows strain conversion in the presence of different amyloid templates, this would be 
important and useful to design therapies that can employ these peptides to delay and even 
prevent disease progression in humans or mammals by converting the prion strain to a 










































GT81-1C [PSI+ PIN+] MATa ade1-14 his3 leu2-3,112 lys2 trp1 ura3-
52 
GT81-1D [PSI+ PIN+] MAT ade1-14 his3 leu2-3,112 lys2 trp1 ura3-
52 
GT409 [psi- pin-] MATa ade1-14 his3 leu2-3,112 lys2 trp1 ura3-
52 
GT159 [psi- PIN+] MATa ade1-14 his3 leu2-3,112 lys2 trp1 ura3-
52 
GT564 [psi- pin-] MATa ade1-14 his3 leu2-3,112 lys2 trp1 ura3-
52 rnq1∆::HIS3Sp 
GT197 [psi- pin-] MAT ade1-14 his3 leu2-3,112 lys2 trp1 ura3-
52 
GT17 [psi- pin-] MATa ade1-14 his3 leu2 trp1 ura3-52 




[PSI+ PIN+] MATa ade1-14 his3-200 leu2-3,112 trp1-289 
ura3-52   
OT55 
(ψ+7-74-D694) 
[PSI+ PIN+] MATa ade1-14 his3-200 leu2-3,112 trp1-289 
ura3-52  
GT671 [psi- pin-] MAT ade1-14 his3Δ (or 11,15) lys2 ura3-52 
leu2-3,112 trp1 sup35::HIS3 [CEN LEU2 
SUP35] 
GT680 [psi- pin-] MAT ade1-14 his3Δ (or 11,15) lys2 ura3-52 
leu2-3,112 trp1 sup35::HIS3 [CEN URA3 
SUP35] 
GT2126 [psi- pin-] MAT ade1-14 his3Δ (or 11,15) lys2 ura3-52 
leu2-3,112 trp1 sup35::HIS3 [CEN URA3 Aβ1-
42-NR-MC] 
GT2132 [psi- pin-] MAT ade1-14 his3Δ (or 11,15) lys2 ura3-52 
leu2-3,112 trp1 sup35::HIS3 [CEN URA3 tau 
RD P301L, V337M-MC] 
GT2132 [psi- pin-] MAT ade1-14 his3Δ (or 11,15) lys2 ura3-52 
leu2-3,112 trp1 sup35::HIS3 [CEN URA3 tau 
RD-MC] 
GT2180 [psi- pin-] MAT ade1-14 his3Δ (or 11,15) lys2 ura3-52 
leu2-3,112 trp1 sup35::HIS3 [CEN LEU2 Aβ1-
42-NR-MC] 
GT2265 [psi- pin-] MATa ade1-14 his3Δ (or 11,15) lys2 ura3-52 
leu2-3,112 trp1 sup35::HIS3 [CEN LEU2 Aβ1-
42-NR-MC] 
GT2266 [psi- pin-] MATa ade1-14 his3Δ (or 11,15) lys2 ura3-52 
leu2-3,112 trp1 sup35::HIS3 [CEN LEU2 
Sup35MC] 
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Table B. Saccharomyces cerevisiae – Escherichia coli shuttle plasmids used in this study 









pLA1 CEN HIS3 PGAL None Ref. 109 
(Newnam et 
al., 1999) 
pLA1-Sup35 CEN HIS3 PGAL SUP35 Ref. 110 
(Chernoff et 
al., 1999);  
ref. 111 
(Chernova 
et al., 2003) 




















CEN HIS3 PGAL SUP35NM-
Aβ1-42 
This study 
pmCUP1 CEN URA3 PCUP1 None Ref. 75  
(Serio et al., 
1999) 
pmCUP1-nERI CEN URA3 PCUP1 None This study 
pmCUP1-PrP90-
231-GFP(URA3) 








CEN URA3 PCUP1 Aβ1-42-GFP This study 
pmCUP1-Sup35N CEN URA3 PCUP1 SUP35N This study 
pmCUP1-Sup35N-
PrP90-230 











































CEN URA3 PCUP1 SUP35N-GFP This study 
pmCUP1-Sup35N-
Ade2 





































































































pLH105 CEN LEU2 PGPD HSP104 Gift of S. 
Lindquist, 




































(F19S, F20S, I31P) 
































































CEN URA3 PCUP1 SUP35N-HA This study 
pmCUP1-Sup35N-
PrP90-230-HA 


























pmCUP1 CEN URA3 PCUP1 None Ref. 75  






















pmSUP35-MC CEN LEU2 PSUP35 SUP35MC Chernoff 
Lab 
Yep13 2micron LEU2 None None Chernoff 
Lab 











Table C. Oligonucleotide primers used in this study 
Name 
 
Sequence 5’-3’ Direction 
























PrP90-119 XbaI GCTCTAGATTATGCCCCAGCTGCCGCAGC Reverse 
PrP90-230 P101L CAGTGGAACAAGCTCAGCAAACCAAAAACC Forward 




PrP90-230 Q167R GTTCTGGTTGCTGTATCGATCCACTGGCCTG Reverse 




Aβ1-42 XbaI TTGTCTAGATTACGCTATGACAACACCGCC Reverse 





ECORI-Myo Pro 2 AATTCGTCGCCAATGCCTTCATCATCTGTGG
CACCTTGTACACCGTCAGCAGCTACTGAT 
Forward 
Myo-XbaI Pro 2 GTCAGTAGCTGCTGACGGTGTACAAGGTGC
CACAGAT GATGAAGGCATTGGCGACAGATC 
Reverse 


























Aβ1-42 D23K GTGGGTTCAAACAAAGGTGCAATCATTG Forward 















































Aß42 MC BamHI  GCGTGGATCCGTCGCCACCATGGATGCAGA
ATTCCG ACATGAC 
Forward 


















Figure A. Qualitative analysis [PSI+] variants induced by N-Aβ-based chimeric 
constructs in yeast. A subset of a spectra of [PSI+] variants induced by various chimeric 
constructs in yeast were scored in comparison to control strong and weak strains, OT56 
and OT55 respectively. [PSI+] variants that had a phenotype ranging in between strong 
and weak [PSI+] variants were scored as intermediate [PSI+] variants. Refer Tables 3-3 
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